Cancer Nanotechnology

Basic,Translational and Clinical Research

Cancer Nanotechnology Cover Image
Open Access

The application of titanium dioxide, zinc oxide, fullerene, and graphene nanoparticles in photodynamic therapy

  • Zahraa Youssef1,
  • Régis Vanderesse2,
  • Ludovic Colombeau1,
  • Francis Baros1,
  • Thibault Roques-Carmes1,
  • Céline Frochot1,
  • Habibah Wahab3,
  • Joumana Toufaily4,
  • Tayssir Hamieh4,
  • Samir Acherar2Email author and
  • Amirah Mohd Gazzali2, 3
Cancer NanotechnologyBasic,Translational and Clinical Research20178:6

https://doi.org/10.1186/s12645-017-0032-2

Received: 20 March 2017

Accepted: 6 October 2017

Published: 19 October 2017

Abstract

Nanoparticles (NPs) have been shown to have good ability to improve the targeting and delivery of therapeutics. In the field of photodynamic therapy (PDT), this targeting advantage of NPs could help ensure drug delivery at specific sites. Among the commonly reported NPs for PDT applications, NPs from zinc oxide, titanium dioxide, and fullerene are commonly reported. In addition, graphene has also been reported to be used as NPs albeit being relatively new to this field. In this context, the present review is organized by these different NPs and contains numerous research works related to PDT applications. The effectiveness of these NPs for PDT is discussed in detail by collecting all essential information described in the literature. The information thus assembled could be useful in designing new NPs specific for PDT and/or PTT applications in the future.

Keywords

NanoparticlesPhotodynamic therapyTitanium dioxideZinc oxideFullereneGraphene

Background

In current era, the explosion of advancement in nanotechnology has opened up different possibilities of its applications, examples being in drug delivery systems, cosmetics, sunscreens, and electronics. The European Union in 2011 has defined nanomaterials as natural, incidental, or manufactured materials containing particles, in an unbound state, as an aggregate or agglomerate, in which at least 50% of the particles exhibit an external size dimension of between 1 and 100 nm (De Jong and Borm 2008; Shi et al. 2013).

In general, nanomaterials such as nanoparticles (NPs) include polymeric NPs, liposomes (multilayer), lipidic micelles (unilayer), quantum dots and metallic NPs (made from different types of metals such as Au, Fe2O3, ZnO, TiO2…), and graphene (Huang et al. 2012). In addition to these groups of NPs, certain specific structures have also been developed including NPs such as dendrimers, fullerenes, cubosomes, and niosomes (Lohani et al. 2014; Voon et al. 2014). The preparation technique of the NPs differs depending on their structures and need, the most common being nano-precipitation technique, solvent evaporation, and lithography technique, to name a few.

The vast diversified types of NPs available to date provides a possibility to pick and choose the most suitable NPs for specific applications. Indeed, the application of NPs is very wide, ranging from cosmetics, engineering, and medicine through pharmaceuticals, among others. In the interest of our research, NPs are being used in the delivery of photosensitizers (PSs) for photodynamic therapy (PDT), which is a good approach to improving their specific site delivery.

PDT is a relatively new treatment modality that has attracted attention since the past 30 years (Yano et al. 2011). Its principal of treatment necessitates the presence of a PS, light of an appropriate wavelength, and molecular oxygen. Among these three components, PS and light are two modifiable factors, and the development of tumor-specific PS is of interest to many researchers in chemistry and pharmaceutical fields (Olivo et al. 2010).

The modification of PS could be performed by conjugation with targeting moieties or using advanced drug delivery systems such as NPs (Wang et al. 2004; Huang et al. 2012). The PS in this kind of conjugate or system is known as the third-generation PS, which has good potential to improve the targeting and delivery of PS towards the diseased tissues. NPs in particular have shown good ability to enhance the delivery of therapeutics through passive targeting by the enhanced permeability and retention (EPR) effect (Blanco et al. 2015). In PDT, the application of NPs has already been used in the formulation of Visudyne®, which is a third-generation PS. In this formulation, its delivery has been shown to be significantly improved (Chang and Yeh 2012).

In the development of third-generation PS, several types of NPs were already being reported in the literature with good potential and positive effect on PDT efficacy. Some representative examples on the use of NPs as anticancer agents are given in the following reviews and can be of interest to the readers (Vanderesse et al. 2011; Couleaud et al. 2011; Benachour et al. 2012; Chouikrat et al. 2012; Monge-Fuentes et al. 2014; Roblero-Bartolon and Ramon-Gallegos 2015; Calixto et al. 2016; Colombeau et al. 2016; Shen et al. 2016; Stallivieri et al. 2016). The nanosize range of NPs is indeed very advantageous because they could penetrate through the fenestration present at the cell junction. Among the different NPs, there are also specific types of particles that have found application in photocatalysis besides being useful in PDT. As examples, the NPs formed by zinc oxide (ZnO), titanium dioxide (TiO2), fullerene, and graphene have shown this dual ability based on a huge number of papers published to date. A review by Lucky et al. (2015) has established in detail the different types of biodegradable and non-biodegradable NPs that are currently available. They have also mentioned the works reported on the development of TiO2, ZnO, and fullerene NPs as downconverting PSs, but the information gathered was only briefly described.

Besides PDT, hyperthermia (and particularly photothermal therapy, PTT) refers to the use of heat in medicine to increase the temperature of human tissues for therapeutic purposes. For example, it has been used for the treatment of cancer tumors, for more rapidly delivering drugs to cancer tissues by increasing blood flow, or in radiotherapy by sensitizing cancer cells using radiation. Cancer cells are naturally more sensitive to radiation than normal cells. Therefore, several protocols, based on hyperthermia, have been developed to destroy tumor cells irreversibly. Indeed, temperatures ranging from 41 to 47 °C can break the membrane of the cells and denature the proteins. Various laser, microwave, radiofrequency, and ultrasonic methods have been tested to localize and destroy tumors. The main drawbacks are the destruction of healthy tissues close to the tumor and the difficulty in obtaining a uniform temperature in the tumor. In order to achieve better targeting of cancer tissues, some authors have proposed to place photo-absorbing agents in the desired region before irradiation by laser radiation. It has been called photothermal therapy (PTT) because photo-absorbing agents convert light into heat. PTT is a minimally invasive, controllable, and efficient sterilization method. In the presence of an external NIR light source, PTT materials convert light energy into heat energy to kill cells. The most commonly used PTT materials include metal nanoscale materials, such as gold, silver, palladium, copper NPs, graphene and carbon nanotubes, and polymeric NPs.

Dual-modal phototherapeutics that combine PDT and PTT can have synergistic effects that enhance therapeutic efficacy compared to PDT or PTT alone.

Poor light penetration could be a limitation to treat deep tumors in the field of research in PDT. A solution that has been related first by the Chen’s team (Chen and Zhang 2006) in 2006 is the use of X-rays, instead of light, combined with NPs as a new PDT modality. Since this date, other teams have developed different kinds of NPs to perform X-ray PDT. Our team (Bulin et al. 2013) synthesized terbium oxide NPs coupled to a porphyrin and showed the formation of 1O2 upon X-ray excitation. Wang et al. (2016) demonstrated the efficiency of SrAl2O4:Eu2+ NPs with MC540 as a Ps co-loaded in mesoporous silica in vivo with a subcutaneous tumor model or H1299 cells into the lung. The use of microwave appears also as a promising alternative as a source of excitation. The microwaves penetrate deeper than UV and visible light, and propagate through all kinds of tissues. This kind of electromagnetic wave can be useful in order to tackle the issue of small penetration of light. Only recently, microwave-induced PDT has emerged as a new and interesting phenomenon (Gu 2013). The proof of concept for this process was reported by Yao et al. using copper cysteamine NPs to destroy rat osteosarcoma cells (Yao et al. 2016). In parallel, graphitic-phase carbon nitride quantum dots have been explored by the same team (Chu et al. 2017) as a new agent for microwave-induced PDT. The singlet oxygen production under microwave irradiation was assessed and the NPs were efficient to kill cancer cells and promote tumor cell death.

Hence, this review is dedicated to bring together all the reported literature to date on the development of ZnO, TiO2, fullerene, and graphene NPs in the specific field of PDT and/or PTT applications.

Zinc oxide nanoparticles (ZnO NPs)

ZnO NPs have long been discovered to have excellent physico-chemical properties as drug delivery vehicles. The Food and Drug Administration (FDA) has recognized ZnO as safe due to its lack of or very weak dark toxicity in vitro and in vivo (Hu et al. 2013).

The advantage that could be firmly associated with ZnO NPs in PDT is their ability to generate visible light upon X-ray radiation. Due to the fact that most currently available PSs absorb light at low wavelength, ZnO NP is a good candidate in improving PDT efficiency because its UV emission upon X-ray excitation more or less matches the UV absorption of most PSs, and hence has a good potential to serve as an irradiation source for PDT on deep-seated tumors. This concept is called self-lighting photodynamic therapy (SLPDT) which was first described by Chen and Zhang (2006) and updated by Sadjadpour et al. (2016).

NPs, due to their small size, have the ability to reach internal organs and tissues through small arteries, veins, and blood capillaries. In the case of ZnO NPs, the unique property described above also allows the NPs to act as a PS themselves in the presence of suitable light dose, hence opening an excellent chance of delivering PDT application to the tumor areas that are difficult to reach by conventional PSs. For the purpose of this review however, we will only focus on the application of ZnO NPs as a carrier for the delivery of second-generation PS. Three types of excitation can be applied: (a) UV-A to excite ZnO NPs, (b) UV–visible to excite PS, and (c) X-ray for fluorescence resonance energy transfer (FRET) between ZnO NPs and PS.

In a work reported by Liu et al. (2008), a conjugate of ZnO–MTAP (meso-tetra(o-aminophenyl)porphyrin) was prepared. Its PDT effects were investigated on a human ovarian carcinoma cell line (NIH:OVCAR-3) and compared with ZnO NPs and MTAP as free molecules. It was shown that the conjugate has significant photocytotoxicity on the cell lines as compared to ZnO NPs or MTAP alone, in which only 10% cells were viable after UV irradiation (365 nm, 30 min) as compared to 98 and 75% for ZnO NPs and MTAP, respectively (Fig. 1). These results suggested that ZnO NP is not cytotoxic to NIH:OVCAR-3 cell lines both in dark and under UV irradiation, while the ZnO–MTAP conjugate showed a significant improvement of photocytotoxicity in the presence of light. The authors estimated 83% of energy transfer efficiency from ZnO to MTAP.
Fig. 1

a Cell viability in NIH:OVCAR-3 cells exposed to either ZnO NPs alone (0.3 μM), MTAP alone (0.075 μM), or ZnO–MTAP conjugates (0.3 μM, ZnO/MTAP ≈ 4/1) under dark conditions (red) or UV illumination (light gray, 365 nm, 30 min, blue). b Excitation (red) and emission (blue) spectra of ZnO NPs

[Taken from reference (Liu et al. 2008)]

They also reported the photophysical properties of the ZnO NPs. The NPs present an excitation peak at 300 nm and two emission peaks at 345 and 445 nm, and hence the emission of ZnO NP overlaps with the absorption band of porphyrin and many other PSs. They proposed that this property could be utilized for the SLPDT concept as mentioned earlier.

In a subsequent study, Zhang et al. (2008) reported singlet oxygen (1O2) production and in vitro cytotoxic effects of the water-soluble ZnO–MTAP conjugate. They used 2,7-dichlorodihydrofluorescein diacetate acetyl ester (CM-H2DCFDA) as a molecular probe and subsequently the fluorescence intensity was determined using a microplate reader under excitation/emission at 485/530 nm. The production of reactive oxygen species (ROS) was dependent on concentration and irradiation dose. Cell viability was estimated through MTT (methylthiazolyl tetrazolium) assay, which has a direct link to mitochondrial enzymes. A reduction in MTT assay was observed in cells which were loaded with ZnO–MTAP conjugate and subsequently irradiated, suggesting that the conjugate was photoactivated, generating ROS and leading to mitochondrial damage and hence reduced cell viability. Only 8% of cells are viable after a co-treatment of UV-A and a higher dose of ZnO–MTAP conjugate (treatment II + IV, Fig. 2).
Fig. 2

a ROS generation by ZnO–MTAP conjugates in the presence or absence of UV-A light. b OVCAR-3 cell viability (20 h later) exposed to ZnO–MTAP conjugates (1 or 10 μM) under dark or UV-A conditions (0 or 9 kJ/cm2 after 4-h exposure)

[Taken from reference (Zhang et al. 2008)]

ZnO nanorods (NRs) conjugated with Photofrin® were investigated by Atif et al. (2011). Hepatocellular carcinoma (HepG2) cell viability was investigated upon exposure to the conjugates and UV light at 240 nm. Even in the absence of UV irradiation, the cell viability in HepG2 cells was found to decrease, although slowly, with increasing conjugate concentration administered from 0 to 800 µg/mL. Around 80% cells remained viable at the highest concentration (Fig. 3a). In the presence of UV light from diode laser light (240 nm), the white light emitted by ZnO NRs activated Photofrin®, which subsequently produced ROS and cell necrosis within few minutes. Hence 77% of cell viability could be observed (Fig. 3b).
Fig. 3

HepG2 cell viability exposed to ZnO NRs conjugated to Photofrin® a in the absence of light and b in the presence of diode laser light (240 nm)

[Taken from reference (Atif et al. 2011)]

The same year, Fakhar-e-Alam et al. (2011a) also reported the application of ZnO NPs conjugated with Photofrin® and 5-ALA (5-aminolevulinic acid) for PDT on HepG2 cells. They observed that both conjugates of ZnO NPs showed minimal toxicity in the absence of light, but they can enhance the fluorescence in the cells due to Photofrin® or protoporphyrin IX (PpIX). ZnO NPs conjugated to 5-ALA were found to better enhance the endogenous fluorescence in the HepG2 cells, as compared to ZnO NPs conjugated to Photofrin®. However, they reported that upon irradiation with visible light at 635 nm, no significant difference in viability of the cells treated with the two conjugates was observed as compared to ZnO NPs alone, implying the inability of the presence of PS in NPs to induce cell death in the HepG2 cells.

In another publication, Fakhar-e-Alam et al. (2011b) tested the cytotoxicity of ZnO NPs in the form of NRs as bare and in conjugation with different PSs which were 5-ALA, Photofrin®, or PPDME (protoporphyrin dimethyl ester) under irradiation at 635 nm on HeLa cells. They reported that the treatment with bare ZnO reduced cell viability by 75%, and the conjugation with PSs showed further reduction of cell viability, 90% reduction for ZnO NPs conjugated to 5-ALA and 80% reduction for ZnO NPs conjugated to Photofrin®. As in the case of PPDME, there was an increase of cell viability at higher conjugate concentrations as compared to the lower ones (Fig. 4). Hence, ZnO–5-ALA and ZnO–Photofrin® conjugates are photocytotoxic on HeLa cells at 635 nm but are less efficient on HepG2 cells in the same conditions.
Fig. 4

Viability of HeLa cells treated with different concentrations of ZnO NRs and their ligands with PSs

[Taken from reference (Fakhar-e-Alam et al. 2011b)]

The same team (Fakhar-e-Alam et al. 2012) published a study on the effect of nanoporous ZnO NPs conjugated with Photofrin® on human lung cancer cells (A549 cells). They found that upon UV irradiation ZnO–Photofrin® conjugate displayed valuable reduction in cell viability as compared to Photofrin® alone. Significant ROS production was observed and about 92% of cells were killed. They also established that the acceptable incubation period for PDT effect is 10–18 h with the optimal time being 12 h. They concluded that ZnO NP has a synergistic effect with Photofrin® and hence a good potential for PDT application in A549 cancer cells.

Fakhar-e-Alam et al. (2014b) explored the application of ZnO NPs in PDT from different angles and application methods, in which ZnO NPs were investigated as a drug delivery vehicle for PSs. Bare ZnO NPs and ZnO NPs PEGylated PpIX were prepared as the model PS and the cell-killing effect on human muscle carcinoma RD cells was tested. In the absence of laser light, ZnO NPs at 1 mM concentration has very low cytotoxicity; 98% of RD cells are viable after a 12 h incubation period, in comparison to the ZnO NPs PEGylated PpIX in which only 85% of cells are viable at a much lower concentration, 0.2 mM. In the presence of laser light (630 nm, 80 J/cm2), the cytotoxicity of ZnO NPs PEGylated PpIX was very evident and the complex induced cell damage. Besides, good localization of the drug was obtained in the tumor area, showing that ZnO NPs are indeed a good drug delivery system.

D’Souza et al. (2015) studied the photophysical properties of phthalocyanines (Pcs) in the presence of ZnO NPs. They proposed that Pc adsorbed on the surface of ZnO NPs spontaneously at an average ratio of 12:1 and subsequent changes in the photophysical properties of the Pcs could be observed. The fluorescence quantum yield of Pc was lower and the fluorescence lifetime is shorter in the presence of ZnO NPs. They concluded that the presence of ZnO NPs influences the fluorescence behavior of Pcs and this could be an advantage in the application of ZnO NPs with Pcs for PDT.

Besides anticancer PDT application, PDT is also effective in antimicrobial therapy. Senthilkumar et al. (2013) investigated the action of ZnO NP-encapsulated TSPP (meso-tetra(4-sulfonatophenyl)porphyrin, Fig. 5a) for antipathogen PDT. It was already known that ZnO NP has the ability to inhibit the growth of different pathogenic bacteria under normal visible light. TSPP which is an anionic PS has low photoinactivation of Gram-negative bacteria such as E. coli. The encapsulation of TSPP in ZnO NPs was believed to be able to increase the photoinactivation of E. coli through increased cellular delivery and improved 1O2 production. They indeed showed that under visible light (400–800 nm), ZnO NP-encapsulated TSPP has significantly higher antibacterial activity as compared to TSPP or ZnO NPs alone (98% activity as compared to 30%). The activity of TSPP alone was negligible on E. coli under visible light (Fig. 5b).
Fig. 5

a Chemical structure of TSPP. b Antimicrobial activity of ZnO, TSPP, and ZnO NP-encapsulated TSPP on E. coli bacterial cells under dark and visible light irradiation

[Taken from reference (Senthilkumar et al. 2013)]

Sadjadpour et al. (2016) studied the synthesis and conjugation of ZnO NPs with two different porphyrins, meso-tetra(4-carboxyphenyl)porphyrin (MTCP) and CuMTCP (Fig. 6a), and their PDT effects on prostate DU145 and breast T-47D cancer cells. The conjugation was performed by first coating the surface of ZnO NPs with l-cysteine and subsequently it was conjugated with the porphyrin. The fluorescence intensity of ZnO NP-coated l-cysteine was mostly quenched at 370 nm after conjugation with porphyrin and a new peak corresponding to the energy transfer between ZnO NP-coated l-cysteine and the conjugated porphyrin molecules appeared. The T-47D cells were more resistant towards PDT treatment by the conjugates as compared to the DU145 cells, and this could be due to the presence of a defense mechanism against NPs uptake by the T-47D cells. Between the two conjugates (ZnO–MTCP and ZnO–CuMTCP), ZnO–MTCP showed higher photocytotoxicity under UV irradiation (UV-A/B, 100 μW/cm2 for 3 min) towards the two selected cell lines as compared to ZnO NPs alone, which indicated an efficient FRET between ZnO and PS (Fig. 6b). In contrast, under X-ray irradiation (0.94 Gy, 30 s), ZnO NPs alone gave significant cytotoxicity on both T-47D and DU145 cell lines, while no cytotoxic effect was observed when the cells were treated with the two conjugates (Fig. 6b). The authors are of the opinion that this may be due to a lack of FRET between ZnO and PS in the conjugated compounds.
Fig. 6

a Chemical structure of ZnO–MTCP conjugate. b Viability of T-47D and DU145 cells incubated with ZnO, ZnO–MTCP, and ZnO–CuMTCP at 60 μM concentration under dark condition, UV irradiation (UV-A/B, 100 μW/cm2 for 3 min), and X-ray irradiation (0.94 Gy, 30 s)

[Taken from reference (Sadjadpour et al. 2016)]

It is also important to note that although ZnO NP is regarded as having the necessary biosafety and biocompatibility profiles and recently its toxicology profile has gained more attention. The toxicity of ZnO NPs is regarded due to its dispersibility. The solubility of ZnO in the extracellular region could lead to an increase in the intracellular Zn2+ level and this might subsequently induce cytotoxicity through certain mechanisms that are still unclear (Pandurangan and Kim 2015). Interestingly, research has shown that surface modification techniques such as PEGylation could reduce its cytotoxicity by reducing its cellular intake (Luo et al. 2014). Surface coating with polymers has also been shown to reduce cytotoxicity as reported by Osmond-McLeod et al. (2014). Another technique called “ron-doping” was also found to have a reduction effect on the cytotoxicity of this particle, example being on lung toxicity as reported in several papers (Xia et al. 2011; Cho et al. 2012). Nevertheless, more studies are needed to determine specifically the mechanism of toxicity and the exact safety conditions of ZnO application as NPs.

In summary, ZnO is a semiconductor material already used for water treatment. More recently, ZnO NPs act as a good candidate for PDT or antimicrobial therapy. Thanks to its small size and the various forms that they can adopt (nanoparticles or nanorods), ZnO–PS systems are good drug delivery systems. Conjugated ZnO–PS systems possess great photophysical properties to obtain a good PDT efficiency and have also evidenced a good ROS production (1O2 and other radicals). Biologically, ZnO–PS systems present good phototoxicity and, more recently, their toxicity have been investigated and some studies showed that the solubility of ZnO in the extracellular region could lead to an increase in the intracellular Zn2+ level inducing cytotoxicity. Other studies are led to determine the safety conditions of ZnO NPs’ utilization. Table 1 below summarized the data available from the literature on the application of ZnO NPs in PDT.
Table 1

Application of ZnO NPs in PDT

Type of NPs (size, nm)

PS (amount)

NPs–PS interactions

Irradiation conditions

Type of ROS

Cancer cell line

Refs.

In vitro

In vivo

NPs (5)

MTAP (4/ZnO)

Conjugated by coupling reaction

UV light 365 nm, 0.51 W/cm2, 30 min

nd

NIH:OVCAR-3

Liu et al. (2008)

NPs (5)

MTAP (4/ZnO)

Conjugated by coupling reaction

UV-A lamp 365 nm, 0.50 W/cm2, 30–120 min

ROS

NIH:OVCAR-3

Zhang et al. (2008)

Nanorods (130–150)

Photofrin and 5-ALA (nd)

Conjugated

Diode laser 630 nm along with UV light of 240 nm, 0–160 J/cm2, 0–20 min

ROS

HepG2

SD rats

Atif et al. (2011)

NPs (80–120)

Photofrin and 5-ALA (nd)

Conjugated

Diode laser 635 nm, 80 J/cm2

nd

HepG2

Fakhar-e-Alam et al. (2011a)

Nanorods (150–200)

Photofrin, 5-ALA and PPDME (nd)

Conjugated

Diode laser 635 nm, 30 J/cm2, 6.5 min

ROS

HeLa

Fakhar-e-Alam et al. (2011b)

Nanoporous (200–600)

Photofrin (nd)

Conjugated

Diode laser, 80 J/cm2

ROS

RD

Fakhar-e-Alam et al. (2012)

NPs (35)

PpIX (nd)

Encapsulated

Laser 630 nm, 80 J/cm2

ROS

A549

Fakhar-e-Alam et al. (2014b)

Nanowires (150–170)

PpXI (nd)

Conjugated

UV-A illumination, light dose 10 J/cm2

ROS

FM55P

AG01518

Fakhar-e-Alam et al. (2014a)

NPs (3–26)

MTCP and CuMTCP (nd)

Conjugated by coupling reaction

UV-A/B (100 μW/cm2, 3 min) or X-ray (0.94 Gy, 30 s) irradiation

ROS

DU145

T-47D

Sadjadpour et al. (2016)

Nanohexagons Nanorods (25–90)

ZnPc

ZnTMAAPc

ZnTMPAPc

(OH)AlPcSmix (Pc: ZnO NPs, 12:1)

Conjugated by coupling reaction

669–690 nm

nd

D’Souza et al. (2015)

NPs (25–40)

TSPP (nd)

Encapsulated

Visible light irradiation

1O2

S. aureus

E. coli

KCCM 12234

KCCM 11256

Senthilkumar et al. (2013)

NPs nanoparticles, PS photosensitizer, ROS reactive oxygen species, nd not disclosed, MTAP meso-tetra(o-aminophenyl)porphyrin, UV ultraviolet, 5-ALA 5-aminolevulinic acid, SD Sprague Dawley, PPDME protoporphyrin dimethyl ester, PpIX protoporphyrin IX, MTCP meso-tetra(4-carboxyphenyl)porphyrin, ZnPc zinc phthalocyanine, ZnTMAAPc 2,(3),9(10),16(17),23(24)-tetrakis-(mercaptoacetic acid phthalocyaninato) zinc(II), ZnTMPAPc 2,(3),9(10),16(17),23(24)-tetrakis-(mercaptopropanoic acid phthalocyaninato) zinc(II), (OH)AlPcSmix mixture of the di-, tri-, and tetra-sulfonated phthalocyanine derivatives, ZnO zinc oxide, TSPP meso-tetra(4-sulfonatophenyl)porphyrin

Titanium dioxide nanoparticles (TiO2 NPs)

Titanium dioxide fine particles (TiO2 FPs) have long been manufactured and used worldwide for different applications. In the past, they were considered to have very low toxicity. However, a finding reported in 1985 has provided a new perspective on its safety. It was found that a chronic exposure of this FPs in mice at a high concentration of 250 mg/m3 for 2 years (6 h/day for 5 days/week) could lead to bronchioloalveolar adenomas and cystic keratinizing squamous cell carcinomas (Lee et al. 1985). However, the detected tumors were different from the common human lung tumors and no metastases could be observed. In the opinion of the researchers, this finding has no biological relevance for human and it is also possible that the tumor was due to overloaded TiO2 FPs instead of specific carcinogenicity of the particles (Lee et al. 1985; Shi et al. 2013).

TiO2 NPs are found to have different physico-chemical properties which may lead to changes in their bioactivity. This NP has been used widely in industrial and consumer products due to their strong catalytic activity (Shi et al. 2013). TiO2 is also known as a wide-band gap semiconductor and is photoactive in the presence of UV light against microorganisms and cancel cells. Efforts have been made to use TiO2 in the form of NP as a support in PDT, by grafting PSs onto the TiO2 NP surface. This grafting enables the use of visible light, instead of UV light for TiO2 alone, in the activation of TiO2 NP-conjugated PS (Jia and Jia 2012). Several studies have shown promising results in the application of these TiO2 NPs conjugated to PS and will be described below.

In the early 2000s, Ion and Brezoi (Ion 2004; Ion and Brezoi 2005a) described the synthesis of a new conjugate TiO2–Sil–TSPP consisting of a coupling between meso-tetra(4-sulfonatophenyl)porphyrin (TSPP) bearing a silane arm (Sil) with TiO2 NPs (Fig. 7). Electronic absorption spectra confirmed the binding of Sil–TSPP to the TiO2 NPs. Atomic force microscopy (AFM) images taken have enabled the determination of the conjugated NP size which was around 39 nm. The in vivo study of this TiO2–Sil–TSPP conjugate on an animal model (mice with implanted cancer cells under skin) showed that the conjugate inhibited tumor growth after laser irradiation (Fig. 8). No further details are given.
Fig. 7

Chemical structure of TiO2–Sil–TSPP conjugate

[Taken from reference (Ion and Brezoi 2005b)]

Fig. 8

Effect of laser before (a) and after (b) illumination (no detail given)

[Reused with permission from reference (Ion 2004)]

Lopez et al. (2010) synthesized via the sol–gel method a TiO2–ZnPc conjugate by the incorporation of ZnPc into the porous network of TiO2 NPs. The different techniques (IR, UV–Vis, Raman spectroscopies) proved that Pc and NPs were linked covalently by the N-pyrrole. The photosensitizing effects of ZnPc, TiO2 NPs, and TiO2–ZnPc conjugate have been studied against four mammalian cells and on two forms of Leishmania parasites (Table 2). Under light irradiation (670 nm), TiO2 NPs were not phototoxic to the cells, as expected. In the same conditions, the treatment with ZnPc was photoactive for all the mammalian cells and a higher phototoxic effect was observed using 597–752 nm irradiation compared to 670 nm irradiation. Nevertheless, the activity against mammalian cells of TiO2–ZnPc conjugate was lower than that of the ZnPc alone. TiO2–ZnPc conjugate had no phototoxicity for Leishmania parasites. The internalization of TiO2–ZnPc conjugate by the cells was lower than that for ZnPc alone. The localization of TiO2–ZnPc conjugate and ZnPc alone was observed in mitochondrial cytoplasm. Finally, the authors concluded that the TiO2–ZnPc conjugate could be a potential PS for PDT treatment.
Table 2

Photoactivity of ZnPc and ZnPc–TiO2 on Leishmania promastigotes and different mammalian cell lines

 

Fluency (J/cm2)

IC50 (μM)

CC50 (μM)

Leishmania parasites

Mammalian cell lines

Chagasi

Panamensis

HDFs

THP-1

HepG2

Vero

ZnPc

0

>15

14.76

9.21

7.74

10.70

0.78

2.5a

12.86

6.63

1.08

0.14

0.28

0.24

2.5b

0.19

0.39

0.15

0.02

0.035

0.09

10a

5.63

5.63

0.05

0.17

0.086

0.038

ZnPc–TiO2

0

> 10

> 10

> 10

> 10

> 10

0.087

2.5a

> 10

> 10

5.51

7.45

> 10

0.079

2.5b

> 10

> 10

3.54

0.28

0.43

0.023

10a

> 10

> 10

nd

2.00

5.50

0.001

ZnPc zinc phthalocyanine, IC 50 concentration that induces 50% of parasite inhibition, CC 50 cytotoxic concentration that induces 50% of cell death, HDFs human-derived fibroblasts, THP-1 human macrophages, HepG2 human heptocellular carcinoma cells, nd not disclosed

aLaser light irradiation (670 nm)

bBiological photoreactor irradiation (597–752 nm)

Gangopadhyay et al. (2015) described the use of TiO2 NPs loaded with 7,8-dihydroxy-4-bromomethylcoumarin–chlorambucil (Ti–DBMC–Cmbl NPs, Fig. 9a) as a targeted combination therapeutic system for MDA-MB-231 breast cancer cells. This conjugate combines the PDT via the coumarin chromophore and the chemotherapy by the chlorambucil drug. Spectroscopic characterizations (IR, UV–Vis, and fluorescence) confirmed the binding of DBMC–Cmbl to TiO2 NPs. The conjugate possess three absorption peaks at 250, 330, and 500 nm. The authors found that the Ti–DBMC–Cmbl NPs have a size of 164.18 nm with good PDT efficiency and a 1O2 quantum yield of 0.29 when excited at 425 nm. The in vitro studies on MDA-MB-231 breast cancer cells showed a good uptake of the conjugate in tumor cells, an inhibited proliferation, and a significant induction of apoptosis (Fig. 9b). Furthermore, for better tumor targeting, they functionalized the Ti–DBMC–Cmbl NPs with folic acid (FA) to target folic acid receptor which is overexpressed on the surface of certain cancer cells (Reddy et al. 2005; Sega and Low 2008). The resulting Ti–FA–DBMC–Cmbl NPs appeared much more efficient than Ti–DBMC–Cmbl NPs after 1 h of irradiation (≥ 410 nm) and the authors observed only ~ 19% cell viability compared to ~ 35% cell viability in the case of the conjugate without FA (Fig. 9b).
Fig. 9

a Chemical structure of Ti–DBMC–Cmbl NPs. b Viability of MDA-MB-231 cells treated with Ti–DMC, Ti–DBMC–Cmbl NPs, and Ti–FA–DBMC–Cmbl NPs (250 μg/mL)

[Taken from reference (Gangopadhyay et al. 2015)]

To improve the cellular uptake of aluminum phthalocyanine chloride tetrasulfonate (AlPcS4, named Pc), Pan et al. (2015) used nitrogen-doped TiO2 NPs (N–TiO2 NPs) to carrier Pc. They obtained the N–TiO2–Pc conjugate by a two-step synthesis: the first step consisted in a silanization reaction of N–TiO2 with 3-aminopropyltriethoxysilane (APTES) to obtain N–TiO2–NH2 followed by the conjugation of Pc. Transmission electron microscopy (TEM) analysis showed that the size was around 25–40 nm for the conjugate. The authors compared the absorption spectra of Pc alone and N–TiO2–Pc conjugate, which expands from 400 to 800 nm, resulting in a 2.6 times better production of ROS under visible light irradiation compared to Pc alone. In vitro studies on HeLa cells (Fig. 10a) and KB cells (Fig. 10b) showed that the cellular uptake of the conjugate was enhanced 6.0 times than Pc alone and its phototoxicity was low. Confocal microscopy allowed to detect N–TiO2–Pc conjugate in the nucleus area. The photokilling effect was also evaluated (Fig. 10) and the results suggested that N–TiO2–Pc conjugate could be an excellent candidate as a PS in PDT.
Fig. 10

Comparative Viability of a HeLa cells and b KB cells treated with Pc, N–TiO2 NPs, and N–TiO2–Pc NPs (250 μg/mL)

[Taken from reference (Pan et al. 2015)]

It is well known that TSPP (see Fig. 5a) possesses adverse effects hampering its potential use in PDT. TSPP enters the cell via endocytosis and localizes in cellular organelle (lysosomes, endosomes, and endoplasmic reticulum) where it interferes with cellular signal pathways, thus producing apoptosis or necrosis (Høgset et al. 2004; Berg et al. 2011). Rehman et al. (2015, 2016b) studied the protective effect of TiO2 nanowhiskers (TiO2 NWs)–TSPP complex in vitro and in vivo. TSPP–TiO2 NWs were prepared by mixing TSPP and TiO2 together. Various concentrations of TiO2 NWs, TSPP, and TiO2–TSPP NWs were injected into rats belonging to four different groups (the fourth group is the control). Histopathology, complete blood cell count (CBC), and fluorescent microscopy were used to evaluate the toxic effects on excretory and circulatory system. The CBC, histopathology, and fluorescent microscopic studies also showed that low concentration TSPP–TiO2 NWs were more secure. The in vitro cytotoxicity was evaluated and a maximum viability was showed for illuminated TSPP–TiO2 NWs group. To conclude, the authors proposed that the use of these TSPP–TiO2 NWs would be adapted for the PDT and bioimaging of cancer or other diseases.

The same team (Zhao et al. 2015, 2016) was interested in the target cellular bioimaging and treatment of rheumatoid arthritis using TiO2–TSSP NPs, which were obtained by mixing a solution of TSPP in phosphate buffer saline (PBS) to a suspension of TiO2 in an acetic acid/sodium acetate buffer. The TiO2–TSSP NPs were characterized by UV–Vis, fluorescence, and IR spectroscopies and zeta potential measurement showing that the porphyrin is covalently linked to TiO2 NPs by the NH-pyrrole. The TSPP loading capacity on TiO2 NPs was about 17.4 wt%. The scanning electron microscopy (SEM) images showed that the TSSP–TiO2 NPs were agglomerated, whereas TiO2 alone had a 30 nm diameter. Figure 11 shows the capability of NPs to produce enough 1O2 and guarantee a good PDT effect. The in vitro studies on the HSC (human rheumatoid arthritis synovial fibroblast cells) and the RSC (murine rheumatoid arthritis synovial fibroblast cells) showed that the TSSP–TiO2 NPs were less cytotoxic than the TSSP alone and demonstrated a good inhibition of the cellular growth of the synovial fibroblast. These NPs act as good candidates for the theranostic biomarkers for rheumatoid arthritis.
Fig. 11

1O2 quantum yield determination a at different time points and b at various concentrations for TSSP–TiO2 NPs and TSPP and TiO2 alone. The 1O2 quantum yields correspond to the 1,3-diphenylisobenzofuran (DPBF) capture rate of 1O2

[Taken from references (Zhao et al. 2015, 2016)]

Lu et al. (2015) studied the PDT effect of Fe- and 5-ALA-modified TiO2 NPs, i.e., Fe/TiO2 and 5-ALA/TiO2 NPs. Fe/TiO2 (2 wt%) and Fe/TiO2 (5 wt%) NPs were synthesized by precipitation method, while 5-ALA/TiO2 NPs were synthesized by ultrasonic method. All the modified TiO2 NPs were characterized by X-ray diffraction and UV–Vis spectroscopy. The characteristic peaks at 1430 and 1730 cm−1 observed on FTIR (Fourier transform infrared) spectra of 5-ALA/TiO2 NPs proved that 5-ALA was covalently bound to TiO2 NPs by an ester link. All the modified TiO2 NPs possess an enhanced absorption in the visible light region. Figure 12 presents the dark toxicity of modified TiO2 NPs to HL60 cells at different concentrations (Fig. 12a). 5-ALA/TiO2 NPs were less toxic to HL60 cells than Fe/TiO2 NPs, but more than that of TiO2 NPs alone. The PDT effect of modified TiO2 NPs was evaluated on HL60 cells after 1-h light exposure at 403 nm. Cell viability with 5-ALA/TiO2, Fe/TiO2 (2 wt%), and Fe/TiO2 (5 wt%) was 19.4, 28.4, and 28.0%, respectively (Fig. 12b). 5-ALA/TiO2 NPs present a promising PDT effect as assessed by the ultrastructural morphology of HL60 cells before and after PDT treatment (Fig. 13).
Fig. 12

a Dark toxicity of TiO2 and modified TiO2 NPs on HL60 cells at different concentrations. b Viability of HL60 cells treated with TiO2 and modified TiO2 NPs upon irradiation (1 h, 403 nm, 5 mW/cm2, 18 J/cm2)

[Taken from reference (Lu et al. 2015)]

Fig. 13

Ultrastructural morphology of HL60 cells. a Normal cultured cells. b PDT-treated cells cultured with 5-ALA/TiO2 NPs

[Reused with permission from reference (Lu et al. 2015)]

In summary, TiO2 is a semiconductor material extensively used in many domains including photocatalytic water treatment, solar cells, sterilization, and more recently anticancer therapy. It embraces a wide range of advantageous properties such as low cost, availability, and biological and chemical inertness. TiO2 can produce a significant cytotoxic effect under UV illumination, accompanied with minor dark toxicity, high stability, and good biocompatibility in vitro and in vivo. However, TiO2 has a UV-limited photoresponse due to its wide band gap. The electronic properties of TiO2 can be easily tuned by linking a PS to its surface. The PS can be either adsorbed or grafted covalently to the surface of TiO2 NPs. The formed TiO2–PS system induces an extension of the absorption profile of TiO2 enabling the use of the visible light for different applications. TiO2, in its nano-metric scale, possesses an appropriate size enabling its use as a carrier of PS to enhance the latter’s uptake into the cells, such as Pc. In addition, conjugated TiO2–PS system has evidenced a good ROS production (1O2 and other radicals). TiO2–PS systems can also serve in the cellular bioimaging. Despite all those good properties, such systems suffer from agglomeration and dispersion issues. Table 3 below summarized the data available on the application of TiO2 NPs grafted with or encapsulating PSs in PDT.
Table 3

Application of TiO2 NPs in PDT

Type of NPs (size, nm)

PS (amount)

NPs–PS interactions

Irradiation conditions

Type of ROS

Cancer cell line

Refs.

In vitro

In vivo

NPs (32–37)

TSPP (1/TiO2)

Conjugated via a silyl linker

Laser irradiation

1O2

Skin tumors from mice

Ion and Brezoi (2005b); Ion (2004)

NPs (nd)

ZnPc (nd)

Encapsulated

Laser light 670  nm, 2.5 or 10 J/cm2, or biological photoreactor 597–752 nm, 2.5 J/cm2

1O2

THP-1

HepG2

Vero

L. chagasi

L. panamensis

Lopez et al. (2010)

NPs (164.2)

DBMC (63.3 μg/TiO2)

Conjugated via an ether linker

UV–visible (≥ 410 nm), 0–60 min

1O2

MDA-MB-231

Gangopadhyay et al. (2015)

NPs (25–40)

AlPcS4 (nd)

Electrostatic attraction

150-W Xe lamp (420–800 nm), 15 J/cm2

ROS

HeLa

KB

(Pan et al. 2015)

NPs (nd)

5-ALA (molar mass ratio 5-ALA:TiO2, 2:1)

H-bonds

403 ± 6 nm, 5 mW/cm2, 18 J/cm2, 60 min

nd

HL60

Lu et al. (2015)

Nanowhiskers (> 100)

TSPP (15.7 wt%)

Physical absorption

Visible light 500–550 nm, 30 min

ROS 1O2

Fibroblast cells from RA joint of SD rats

Male SD strain rats and DBA-1 mice with RA disease

Zhao et al. (2015)

Nanowhiskers (30)

TSPP (17.4 wt%)

Charge transfer

Green light 500–550 nm, 5 mW/dm2, 10 min

1O2

HSC

RSC

Zhao et al. (2016)

Nanowhiskers (nd)

TSPP (nd)

Ionic bonding

Visible LED light (500–550 nm), 5 mW/dm2, 5 min for in vitro and 60 min for in vivo

ROS

1O2

RA infected BMS cells

BMS cells from the RA infected murine models

Rehman et al. (2015)

Nanowhiskers (nd)

TSPP (concentration TiO2:TSPP, 6:1)

Solution mixture

Green light 500–550 nm, 60 min

ROS

1O2

Fibroblast primary cells from SD rats

Male SD rats

Rehman et al. (2016b)

Nanowhiskers (nd)

TSPP (concentration TiO2:TSPP, 10:1)

Absorption

Visible light 500–550 nm, 60 min

ROS

1O2

Diabetes mellitus murine model (type I and type II)

Rehman et al. (2016a)

NPs nanoparticles, PS photosensitizer, ROS reactive oxygen species, nd not disclosed, TSPP meso-tetra(4-sulfonatophenyl)porphyrin, ZnPc zinc phthalocyanine, DBMC 7,8-dihydroxy-4-bromomethylcoumarin, UV ultraviolet, AlPcS 4 aluminum phthalocyanine chloride tetrasulfonate, 5-ALA 5-aminolevulinic acid, SD Sprague Dawley

Fullerene

Fullerene C60 has been evidenced by Kroto et al. (1985) who were awarded the 1996 Nobel Prize in Chemistry for this important discovery. From that point, this redox-active chromophore and its analogues were thoroughly studied for their electron and energy transfer ability to form artificial photosynthetic systems (Martin et al. 1998). Thus, a large number of intermolecular C60 charge transfer dyads were described either with electron donor molecules such as ferrocenes (Crane et al. 1992), cobaltocenes (Stinchcombe et al. 1993), or polymers (Zhang et al. 2014). In addition, numerous covalently linked C60–Donor dyads have been synthesized in several ways (Hirsch 1995), i.e., 1,3-dipolar cycloaddition (Maggini et al. 1993; Meier and Poplawska 1996), Diels–Alder (Belik et al. 1993), or Bingel–Hirsch (Bingel 1993; Cho et al. 2014) reactions.

Functionalized fullerenes alone can be considered as PSs usable for the medical applications as, for example, the treatment of mice infected by Gram-negative bacteria (Sharma et al. 2011; Huang et al. 2014). PDT applications have also been investigated and various cancers such as metastatic cancer in peritoneal cavity were studied. Tokuyama et al. (1993) were the first to show that fullerenes substituted by carboxylic acids could be phototoxic to HeLa cells. In the same way, it has been shown that the action of pristine C60 and light could be used for the treatment of Ehrlich carcinoma cells or infected thymocyte eradication in rat (Burlaka et al. 2004). Currently, research focuses more on the treatment of pathogenic infections by substituted fullerenes in the presence of light than on light-mediated PDTs of cancers and only few research articles have been submitted in the two last years, the most important being cited in the following references (Wang et al. 2014; Shi et al. 2014, 2016; Li et al. 2015b; Liu et al. 2015b; Yu et al. 2016).

As already mentioned, the subject of this review concerns the use of dyads in which a PS (electron donor) and a fullerene (electron attractor) can give rise to a PDT effect mainly due to light-induced electron transfer. An interesting review entitled “Fullerene–porphyrin nanostructures in photodynamic therapy” has been published by Constantin et al. (2010).

One general protocol to functionalize a fullerene is the Bingel–Hirsch reaction (Bingel 1993) which is a two-step cyclopropanation by a Michael addition of a α-halocarbanion followed by the expulsion of the halogen and subsequent malonate formation (Fig. 14).
Fig. 14

Example of malonic functionalization of fullerene

This malonic functionalization of fullerene has been widely studied to design new molecules usable for PDT application. However, it is known that [C60] fullerene malonic acid derivatives (MA–C60) can induce damages to cytoplasmic and mitochondrial membranes (Yang et al. 2007).

The other classical protocol to substitute a fullerene is the Prato reaction (Maggini et al. 1993) which can proceed in two ways involving the addition of azomethine ylide to fullerene (Fig. 15).
Fig. 15

Substitution of fullerene by Prato reaction

Durantini’s group (Milanesio et al. 2002) designed 5-(4-amidophenyl)-10,15,20-tris(4-methoxylphenyl)porphyrin–fullerene dyad (P–C60) free base or metallated by Zn(II) (Fig. 16a). The synthesis involved the condensation of 1,2-dihydro-1,2-methanofullerene[60]-61-carboxylic acid (Fungo et al. 2001) and an aminoporphyrin (Fungo et al. 2000). Compared to porphyrin alone, the P–C60 dyads exhibited a lower emission than that of the porphyrin alone, resulting from quenching of the fullerene entity (Milanesio et al. 2005). 1O2 production quantum yield (Φ Δ) was dependent on the polarity of the solvent and Φ Δ diminished considerably in DMF (Φ Δ = 0.18) vs toluene (Φ Δ = 0.80). For the in vitro studies on Hep-2 human larynx carcinoma cell line, the dyads were added from a liposomal solution due to their low solubility in PBS. Only the free base porphyrin P–C60 exhibited interesting properties (Alvarez et al. 2006) and was further studied. The P–C60 uptake occurred at a concentration of < 1.5 nM/106 cells after 5–8 h. After incubation with P–C60 (1 μM) and irradiation at a wavelength range between 350 and 800 nm and at 54 J/cm2, the cell survival was about 20 and 50% under the atmosphere of air or argon, respectively (Alvarez et al. 2006, 2009) (Fig. 16b).
Fig. 16

a Chemical structure of free base P–C60 dyad. b Inactivation of Hep-2 cells irradiated with visible light (0–54 J/cm2) in atmosphere of air or argon (1 μM of P–C60, incubation time 24 h)

[Taken from references (Alvarez et al. 2006, 2009)]

The same group (Belen Ballatore et al. 2014) described the synthesis of a similar porphyrin–fullerene dyad P–C60 (Fig. 17a) via a Prato reaction in which a N-ethylcarbazole moiety was introduced at the meso positions. This dyad was investigated for the photoinactivation of S. aureus and E. coli. The bacterial suspensions were incubated and irradiated by visible light at different time intervals. This dyad inactivated more than 99% of S. aureus at a concentration of 5 μM in 30 min at 37 °C (Fig. 17b). The activity (25%) against the Gram-negative E. coli was found to be lower but significant in the same conditions.
Fig. 17

a Chemical structure of P–C60 dyad. b Photoinactivation of S. aureus by P–C60 fullerene at different concentrations and at a wavelength range between 350 and 800 nm

[Taken from reference (Belen Ballatore et al. 2014)]

Recently, Shu’s group (Guan et al. 2015a) included P–C70 dyads in upconversion NPs (UCNPs) which included a core of lanthanide (Gd, Y, Tm) wrapped electrostatically by P–C70 (P = trismethylpyridylporphyrin, TMPyP) and finally coated by folic acid-modified PEG. This UCNP–PEG–FA/P–C70 nanocomposite can act as a theranostic tool with folic acid (FA) as a targeting agent, PEG for furtivity, lanthanide for trimodal imaging (fluorescence/upconversion luminescence/magnetic resonance imaging), and P–C70 dyad for photoinduced therapy. The UV emission of UCNP matched with the absorption at 290, 345, and 361 nm, and visible emission at 451 and 475 nm of P–C70. The in vitro viability of HeLa-luc cells decreased with the concentration of UCNP–PEG–FA/P–C70 and 95% of cell death was obtained at a concentration of 0.2 mg/mL upon NIR irradiation (980 nm, 480 J/cm2) (Fig. 18a). Only 50% of cell death was observed in hypoxic condition. As illustrated in Fig. 18b, the in vivo growth of tumor cells was considerably decreased with UCNP–PEG–FA/P–C70 in the presence of light compared to controls.
Fig. 18

a Viability of HeLa-luc cells incubated with UCNP–PEG–FA/P–C70 at various concentrations. b Growth of tumors after treatments. The relative tumor volumes were normalized to their initial sizes. c Viability of A549, HBE, and HeLa-Luc cells incubated with either UCNP–PEG–FA/P–C70 or the mixture of UCNP–PEG–FA/P–C70 and an excess of folate (980 nm, 480 J/cm2)

[Taken from reference (Guan et al. 2015a)]

During the same year, Shu’s group (Guan et al. 2015b) revisited also the results on P–C60 dyad obtained by Alvarez and co-workers (2006) and synthesized an amphiphilic dyad porphyrin–C70 (P–C70) according to a previous methodology (Xu et al. 2011) by coupling the water-soluble 5-(4-formylphenyl)-10,15,20-tris(4-pyridyl)-porphyrin (D-TMPyP) with fullerene C70 via a Prato reaction (Maggini et al. 1993) (Fig. 19a). The P–C70 dyad formed a self-assembled liposomal structure with a diameter of ca. 30 nm. The P–C70 cellular uptake by A549 cells was threefold better than that of the porphyrin alone (D-TMPyP) and confocal microscopy showed that P–C70 was localized as small clusters in the cytoplasm. After 3-h incubation and 10-min irradiation at 405 nm (17 mW/cm2), the efficacy of cell killing was about 98% at a concentration of 1 μM/L under air atmosphere (Fig. 19b). More interesting is the efficiency of PDT under anaerobic conditions (Fig. 19c). Under the same conditions, but also nitrogen, the damages reached 80% for P–C70 and only 22% for D-TMPyP alone. Mechanism of this surprising PDT effect has been studied. While 1O2 is responsible for the damages in aerobic conditions, the formation of other ROS is involved under hypoxic condition, particularly from P–C70. The longer triplet lifetime of P–C70 (211.3 μs) can be assigned to the exciplex formed by energy transfer between the excited porphyrin and the ground state C70. All of these properties made P–C70 dyad an ideal candidate for anticancer PDT under shallow and hypoxic conditions. It has to be noted that Lee et al. (2001) published the synthesis of similar covalently linked chlorin–fullerene dyads formed by coupling methyl-pyropheophorbide-a and C60 in toluene at reflux without performing any PDT assays.
Fig. 19

a Chemical structure of P–C70 dyad. b Viability of A549 cells incubated with P–C70 at gradient concentrations for 3 h and exposed to white light irradiation (17 mW/cm2, 10 min). c Viability of A549 cells incubated for 3 h with P–C70 and D-TMPyP (2 μM concentration) alone or in the presence of different ROS quenchers upon light irradiation for 10 min (white light irradiation, 17 mW/cm2) under air or nitrogen conditions

[Taken from reference (Guan et al. 2015b)]

Very recently, the same group (Guan et al. 2016) described the production and the properties of fullerene C70 nanovesicles (noted FCNVs) made from C70–oligo ethylene glycol–Ce6 (Fig. 20a) which contained both hydrophilic and hydrophobic parts. These FCNVs have a high loading efficiency of Ce6 (57 wt% on tri-malonate derivative of fullerene C70 named TFC70) and efficient absorption in near-infrared spectroscopy could be observed. The diameter was estimated to be 31 nm as assessed by SEM, and AFM images indicated that the FCNVs are hollow spheres. In vitro experiments on A549 cells in the presence of NaN3 (1O2 quencher) clearly showed that cell death was due to 1O2. The 1O2 production was higher for the FCNVs than for Ce6 alone due to better absorption at 660 nm. Furthermore, negligible cytotoxicity was observed at concentrations up to 0.2 mg/mL. Figure 20b clearly shows the excellent ability of FCNVs to kill A549 cells as compared to Ce6 and TFC70 alone. Figure 20c shows the relative tumor volume 4 h after i.v. injection (10 mg/kg) and irradiation with 660-nm laser (0.1 W/cm2 for 10 min). The half-life of the FCNVs was shown to be 73.6 h (13.2 h for Ce6) indicating longer blood circulation than for the free Ce6.
Fig. 20

a Chemical structure of FCNVs. b Viability of A549 cells incubated with FCNVs, free Ce6, and TFC70 (0.1 mg/mL). c Growth of tumors after treatments. The relative tumor volumes were normalized to their initial sizes

[Taken from reference (Guan et al. 2016)]

Rancan et al. (2005, 2007a, b) proposed fullerene–pyropheophorbide-a conjugates as new tools for PDT. They synthesized different complexes starting from bis-malonato-pyropheophorbide-a up to decakis-pyropheophorbide-a[5:1]fullerene hexaadduct. They compared the uptake, photoinduced cytotoxicity, and photosensitizing activity of mono- (FP1) and hexaadducts (FHP1) towards human leukemia T lymphocytes (Jurkat cells) with free pyropheophorbide-a (Pyro-a) as a reference (Fig. 21) (Rancan et al. 2005).
Fig. 21

Chemical structures of mono- (FP1) and hexaadducts (FHP1)

[Taken from reference (Rancan et al. 2005)]

Intracellular uptake of these derivatives showed a better accumulation than that of Pyro-a alone. This can be due to the size of adducts and a better diffusion through the plasma membranes of the small molecules when compared to the bigger ones, the uptake of which can occur only by endocytosis or pinocytosis. Nevertheless, the adduct FHP1 showed a better cytotoxic activity than FP1 with a 58% cell death when irradiated at 688 nm and 400 mJ/cm2.

Two years later, the same group (Rancan et al. 2007a, b) described the synthesis of hexamalonato-fullerenes bearing 6 (FHP6) and 12 Pyro-a moieties (FHP12) (Fig. 22).
Fig. 22

Chemical structures of hexamalonato-fullerenes with 6 Pyro-a units (FHP6) and 12 Pyro-a units (FHP12)

[Taken from references (Rancan et al. 2007a, b)]

They showed that FHP6 exhibited a five times higher intracellular uptake than FHP1 and 40 times higher uptake than FHP12 but significantly lower than Pyro-a alone (Rancan et al. 2007b). In a last assay, they conjugated the decakis-pyropheophorbide-a[5:1]fullerene hexaadduct adipinic acid active ester with the monoclonal antibody Rituximab as an addressing unit. This antibody binds to the membrane of the CD20 receptor, which is overexpressed by cancer B cells. The affinity for the receptor was conserved as assessed by confocal microscopy (Rancan et al. 2007a). Unfortunately, the cell viability was 70% with Rituximab and the hexaadduct adipinic ester. No further results were published.

Ion et al. (2010) synthesized a tetraphenylporphyrin (TPP)–poly(vinylpyrrolidone) (PVP)–C60 (TPP–PVP–C60,) triad formulation (Fig. 23). The system was stabilized by electrostatic interactions between the three components, donor–acceptor bonds between C60, TPP, and PVP. In vitro studies have been performed on K562 leukemia cell lines: no dark toxicity was observed with a concentration up to 0.5 μM after 18 h of incubation. In the same conditions and under irradiation (436 nm, 0–1 J/cm2, 20–200 mW/cm2), only 20% of cells remained alive (80% without triad).
Fig. 23

Chemical structure of TPP–PVP–C60 triad

[Taken from reference (Ion et al. 2010)]

The in vivo experiments were performed on tumor-bearing rats (Walker 256 carcinoma) treated with TPP–PVP–C60 (10 mg/kg) (Ion et al. 2012). In tumor, the concentrations of lipid peroxides and protein carbonyls increased significantly, while those of the thiol groups decreased indicating a strong tumoral oxidative process. No further results were reported.

Guo et al. (2014) co-encapsulated malonic acid–fullerene (MA–C60) and docetaxel (DTX) in PEG–PLA micelles as delivery carriers. The average diameter was about 37 nm as assessed by TEM images. The viability of HeLa cells decreased with the co-entrapping of both MA–C60 and DTX (40% in the dark and 10% upon light irradiation at 339 nm after 72 h). After i.v. injection in S180 tumor-bearing mice, bioavailability of the MA–C60/DTX NPs was 2.25-fold higher than that of DTX micelles and a tumor growth inhibition rate of 81.3% at a 15 mg/kg dose was observed after 14 days (61.2% for DTX micelles).

Zhang’s group (Li et al. 2014) described 5-ALA-loaded fullerene vesicles (C60–5-ALA) obtained by dripping 5-ALA sodium salt into a toluene solution of fullerene C60. The diameter of the NPs has been estimated to be about 80–200 nm by DLS (Dynamic light scattering) and the loading of 5-ALA at the periphery of C60 was found to be 45 wt% as assessed by thermal gravimetric analysis. The PpIX generation was estimated after incubation, disruption, and extraction of B16-F10 cells (Fig. 24a). In tumor-bearing mice, PpIX induced by 5-ALA alone was found in almost all the tissues, while it is more selective for the tumoral tissue and lungs with C60–5-ALA. With 5-ALA alone, PpIX formation reached the maximum at 2 h and then rapidly decreased, while C60–5-ALA induced the maximum after 4 h. Furthermore, the authors observed an enhanced cell-killing effect with C60–5-ALA after irradiation at 630 nm (49% for C60–5-ALA and 32% for 5-ALA alone). Moreover, the tumor volume was stable after 11-day treatment, which was not the case for 5-ALA or irradiation alone (Fig. 24b).
Fig. 24

a PpIX synthesis from 5-ALA or C60–5-ALA in tissues as a function of time. b Growth of tumors after PDT treatment (630 nm, 0.1 W/cm2, 0.5 min) with 5-ALA or C60–5-ALA

[Taken from reference (Li et al. 2014)]

Laptev et al. (2009) applied for a patent in which they described a pharmaceutical formulation for PDT of malignant tumors. They described the synthesis and the PDT assays of C60–PSs covalently bound to an amino acid or a dipeptide (Arg–Arg) and their combination with biocompatible synthetic biopolymers. Toxicity was only observed after 3–5 h post administration (adynamia, ruffling of hair, and absence of protecting reflex) but the animals return quickly to a normal state as assessed by histological analyses of the liver, kidney, spleen…. after 1 week of administration. The in vivo PDT bioassays (615–680 nm region) were carried out on BALB/c mice with lymphogenically metastasizing or hybrid mice F1 (CBA + C57/B6) with intraperitoneally transplanted embryocarcinoma. Qualitatively, the administration of the composition was characterized by the formation of a scab in the first 3–5 days and the necrosis in the tumor node which can reach 7–9 mm in depth.

Fullerene: potential conjugates

Kotelnikov et al. (2013) described two covalently linked conjugates between C60 and ruboxyl (Fig. 25). While ruboxyl and fullerene alone exhibit no or low PDT activity when irradiated at 500 nm, ruboxyl can interact with the fullerene moiety via energy and/or electron transfer. Thus, under visible irradiation at 500 nm, the resulting excited fullerene produced superoxide radical anion (O 2 ·‒ ). Furthermore, the presence of a chlorine atom on the fullerene induced a 30% gain of the O 2 ·‒ production as assessed by NBT (nitroblue tetrazolium) test. These potential PDT properties could be of interest for biomedical applications in cancer, virus, or bacterial treatments.
Fig. 25

Conjugates between C60 and ruboxyl

[Taken from reference (Kotelnikov et al. 2013)]

As a promising tool in PDT and triplet–triplet annihilation upconversion (TTA-UC), Zhao’s team (Wu et al. 2012) described the photophysical behavior of two light-harvesting fullerene dyads as triplet PS (Fig. 26). Two conjugates BDP–C60 and Bis-BDP–C60 were synthesized from boron-dipyrromethene (BDP) and C60 by a Prato reaction. These heavy atom free molecules are efficient and exhibited upconversion quantum yields up to 7% and a strong absorption of visible light at 515 nm for BDP–C60 dyad and 590 nm for Bis-BDP–C60 dyad.
Fig. 26

Light-harvesting fullerene dyads BDP–C60 and Bis-BDP–C60

[Taken from reference (Wu et al. 2012)]

In the PDT field, the measurement of oxygen concentration during PDT is a particularly challenging problem due to real-time changes in oxygen demand and supply during the treatment. Starting from similar P–C60 dyad, Mermut et al. (2009) studied its use as a novel optical oxygen sensor in PDT. They related the measurement of O2 concentration during PDT by analyzing the magnetic field effect which can discriminate between the type I and type II photodynamic pathways, and proposed a new tool for controlling the intersystem crossing between singlet and triplet states using a fullerene linked to Zn or Cu porphyrin in liposome cell phantom.

Since their discovery in the 1980s, fullerenes (C60 and C70) have fascinated researchers. Fullerenes are semiconductor materials and used as organic photovoltaics, catalysts, antioxidants, in water purification, biohazard protection… and, quite recently, as nanomedicines. The formulation of this kind of nanomaterials involving fullerenes can be done in several ways, e.g., liposomes, micelles, dendrimers, or nanovesicles, and can be used in various fields of medicine such as antibacterial, PDT, PTT, or dual PDT/PTT agents. For example, functionalized fullerenes with carboxylic acid groups have found application in PDT as PSs due to their electron and energy transfer ability. Fullerenes can also act as n-type semiconductors (electron acceptors) and be conjugated with p-type porphyrins (electron donors) to develop dyads giving rise to a PDT effect mainly due to a light-induced electron transfer. At present, some researchers have started to develop bimodal protocols involving diagnosis/therapy, PDT/PTT, or aerobic/hypoxic conditions and these bimodal approaches seem to be the most promising. Table 4 below summarized the data available on the application of fullerene NPs grafted with or encapsulating PSs in PDT.
Table 4

Application of fullerene NPs in PDT

Type of NPs (size, nm)

PS (amount)

NPs–PS interactions

Irradiation conditions

Type of ROS

Cancer cell line

Refs.

In vitro

In vivo

Liposomes (nd)

ATMP (1/C60)

Conjugated

150 W lamp 350–800 nm, 54 J/cm2

1O2

Hep-2

Alvarez et al. (2006)

Liposomes (nd)

AcTMP (1/C60)

Conjugated

150 W lamp 350–800 nm, 54 J/cm2

1O2

Hep-2

Alvarez et al. (2009)

Reversed micelles (nd)

FTEP (1/C60)

Conjugated via 1,3-dipolar cycloaddition

Visible light (350–800 nm), 0.2 W/cm2, 8 J/cm2

1O2

S. aureus

E. coli

Belen Ballatore et al. (2014)

Liposomes (30)

D-TMPyP (1/C70)

Conjugated

White light 400–700 nm, 17 mW/cm2, 5–20 min

ROS

1O2

A549

HaCaT

Guan et al. (2015b)

Liposomes (20)

TMPyP (1/C70)

Conjugated

Laser 980 nm, 0.8 W/cm2, 10 min

1O2

HeLa-luc

A549

HBE

HeLa-luc tumor-bearing female BALB/c nude mice

Guan et al. (2015a)

Nanovesicles (31)

Ce6 (57 wt%)

Conjugated to C70 via the OEG2 linker

Laser 660 nm, 20 mW/cm2 (in vitro) or 0.1 W/cm2 (in vivo), 10 min

1O2

A549

4T1-luc tumor-bearing female BALB/c mice

Guan et al. (2016)

Micelles (37)

DTX (< 80 wt%)

Encapsulated

Diode laser 532 nm, 0.1 W/cm2, 5 min

ROS

HeLa

S180 tumor-bearing mice

Guo et al. (2014)

Supramolecular assemblies (nd)

TPP (nd)

H-bonds

Electrostatic

Hg lamp, equipped with an UV39 filter, 436 nm, 20–200 mW/cm2, 0–1 J/cm2

nd

K562

Ion et al. (2010)

Supramolecular assemblies (nd)

TPP (2/C60)

H-bonds

Electrostatic

Red light 635 nm, 50 J/cm2, 15 min

ROS

Walker 256 tumor-bearing Wistar rats

Ion et al. (2012)

Complexes (nd)

Ce6 and ZnCe6 (nd)

nd

A) Laser 662 nm and 890 nm, 100 J/cm2

B) Laser 615–680 nm

1O2

A) Embryocarcinoma bearing F1 hybrid female mice (CBA and C57/B6)

B) Lymphogenically metastasizing embryocarcinoma bearing female BALB/c mice

Laptev et al. (2009)

Complexes (nd)

Pyro-a (2/C60)

Conjugated

Laser diode 668 nm, 2.12 mW/cm2, 0.5 and 3 min

1O2

Jurkat

Rancan et al. (2005)

Dendrimers (nd)

Pyro-a (6 or 12/C60)

Conjugated

nd

1O2

Jurkat

Ramos

EBV transformed

B-lymphocytes

Rancan et al. (2007a)

Dendrimers (nd)

Pyro-a (2, 6 or 12/C60)

Conjugated

Laser diode 668 nm, 2.12 mW/cm2, 0.5, 1 and 3 min

1O2

Jurkat

Rancan et al. (2007b)

NPs (80–200)

5-ALA (45.12 wt%)

5-ALA complexed with C60

Laser 630 nm, 0.1 W/cm2, 0.5 min

nd

B16-F10

B16-F10 mice melanoma

Li et al. (2014)

NPs nanoparticles, PS photosensitizer, ROS reactive oxygen species, nd not disclosed, ATMP 5-(4-amidophenyl)-10,15,20-tris(4-methoxyphenyl)porphyrin, AcTMP 5-(4-acetamidophenyl)-10,15,20-tris(4-methoxyphenyl)porphyrin, FTEP 5-(4-formylphenyl)-10,15,20-tris[3-(N-ethylcarbozoyl)] porphyrin, TMPyP trismethylpyridylporphyrin, D-TMPyP 5-(4-formylphenyl)-10,15,20-tris(4-pyridyl)-porphyrin, Ce6 chlorin e6, OEG2 1,10-diamino-4,7-dioxadecane, DTX docetaxel, TPP tetraphenylporphyrin, UV ultraviolet, Pyro-a pyropheophorbide a, 5-ALA 5-aminolevulinic acid

Graphene and graphene oxide

Graphene is a relatively new material recently isolated in 2004 by Novoselov et al. (2004), which has an extremely huge potential. It is a single layer of graphite, and its structure and physico-chemical properties permit its applications in different areas ranging from flexible electronics to DNA sequencing (Ahn and Hong 2014; Ojha et al. 2014; Raccichini et al. 2015). Starting from graphene, there are different two- and three-dimensional structures that can be produced and used as drug carriers (Fig. 27). Among these structures, we can cite single-walled carbon nanotubes (SWCNTs, rolled-up graphene monolayers), fullerenes (wrapped-up graphene, see fullerene NPs part), and graphite (stacked-up graphene monolayers). Graphene oxide (GO) and reduced graphene oxide (rGO) are, meanwhile, obtained after oxidation and oxidation/reduction processes, respectively (Fig. 27). Graphene is known, among other things, for its good electrical conductivity thanks to a two-dimensional (2D) network of sp2-hybridized carbon atoms.
Fig. 27

Chemical structures of graphene and its descendants

Oxidation of graphene to GO causes the loss of the sp2 carbon network, i.e., GO becomes an electrical insulator, and the formation of several oxygen-containing functional groups (hydroxyl, carboxyl, and epoxy groups). The presence of oxygen atoms gives the GO better hydrophilicity than graphene, making it easier to disperse in organic solvents, water, and different matrixes. The reduction of GO to rGO is needed to restore electrical conductivity but this causes a considerable reduction of its dispersity due to its tendency to produce aggregates.

Numerous reviews report on the use of graphene or GO as drug carriers (Krishna et al. 2013; Dong et al. 2014; Wu et al. 2015). The first advantage relies on their large surface area. Another advantage arises from the ππ structure of graphene which can easily bind to aromatic structures, which is often the case for PS. In the field of cancer therapy and/or diagnosis, 73% of the articles focus on drug-delivering applications and 27% on theranostic applications (Orecchioni et al. 2015). In cancer therapy and particularly in PDT, some reviews (Shen et al. 2012; Goncalves et al. 2013; Rahman et al. 2015; Li et al. 2015a) can be useful for scientists.

Graphene and single-walled carbon nanotubes (SWCNTs)

Graphene for PDT applications

Liu et al. (2015a) published an interesting article describing the direct one-pot synthesis of graphene (G) loaded with Ce6 via ππ stacking interactions by a simple sonification of Ce6 and graphite in an aqueous solution (loading efficiency 160 wt% and exfoliation yield 9%). During the Ce6 loading, graphite is progressively exfoliated to G to form G–Ce6 nanocomposite. In addition to having the advantage of directly producing graphene-based PS without going through an oxidizing step to generate GO, the authors found that the G–Ce6 displays remarkable characteristics. First, the Ce6 loading for G is tenfold higher than that for GO analogues, and no functionalization of G is required to obtain good dispersibility in physiological conditions. The in vitro study of G–Ce6 (HeLa cells, laser irradiation 660 nm for 2 min) provided evidence of ROS generation and showed that the concentration necessary to kill cells with G–Ce6 is 6–75 times lower than in any other Ce6 composites including GO–Ce6. This result opens the path to drawing up new graphene-based PS as nanocarriers for PDT.

Wu et al. (2014) studied the synergistic activity of polylysine–graphene (G–PLL) formulated with doxorubicin (Dox) and Zn(II) phthalocyanine (ZnPc). The nanocomplex was easily prepared by self-assembling ZnPc and Dox on G–PLL and showed high solubility and stability in biological media. It was found that the 1O2 production was lower than that of ZnPc alone, but besides it was also shown that the activity of the PS may be restored after release (Zhu et al. 2008; Tian et al. 2011). The cytotoxicity to HeLa cells was found to be negligible; however, when subjected to irradiation (660 nm, 0.15 W/cm2 for 10 min), a 90% loss of viability was observed with an IC50 of 0.14 μg/mL. This synergistic effect was also observed with MCF-7 (IC50 = 0.21 μg/mL) and B16 mouse melanoma cells (IC50 = 0.28 μg/mL).

SWCNTs and PDT applications

Zhu’s team (Xiao et al. 2012) studied the chemical characteristics and PDT efficacy of SWCNTs–Ce6–chitosan nanorods. The obtained nanorods had an overall diameter of 6–7 nm with a thickness of PS of about 1.2 nm. The dark toxicity of SWCNTs–Ce6–chitosan (100 μg/mL) was found to be less than 20% after 48-h incubation with NIH/3T3 normal cells. The PDT effect of SWCNTs–Ce6–chitosan to HeLa cells was determined in vitro by WST-1 assay and showed that the IC50 value of free Ce6 is about 8.80 ± 0.059 μg/mL, while that of the nanocomposite is only 5.98 ± 0.064 μg/mL probably due to better hydrophilicity (Fig. 28).
Fig. 28

In vitro PDT effect of SWCNTs–Ce6–chitosan on HeLa cells (663 nm, 150 mW/cm2, 10 min)

[Taken from reference (Xiao et al. 2012)]

Ogbodu and co-workers (2014; Ogbodu et al. 2013a, b, 2015a, b) studied SWCNTs with 1–5 nm diameter and 1–5 μm length as nanocarriers of several zinc phthalocyanine–X (ZnPc–X) conjugates (Table 5). These conjugates were adsorbed onto SWCNT via ππ stacking interactions. They presented better photophysical properties than the ZnPc alone. The in vitro phototoxicity experiments were performed with ZnMAPc–FA–SWCNT and ZnMAPc–spermine–SWCNT on human skin melanoma A375 and MCF-7 breast cancer cells, respectively. After diode laser irradiation (676 nm, 98 mW/cm2, 5 J/cm2) in the presence of ZnMAPc–FA–SWCNT at 10 μM, a PDT effect was observed with a 37% cell viability compared to 40% with ZnMAPc–FA and 77% with SWCNT–FA, showing that SWCNT does not have a significant PDT or PTT effect on the cells (Fig. 29).
Table 5

ZnPc–X conjugates

ZnPc

X

Refs.

ZnMAPc

Pyrene

Ogbodu et al. (2013b)

ZnMAPc

Folic acid

Ogbodu et al. (2013a, 2015b)

ZnOPc

Bovine serum albumin

(Ogbodu and Nyokong 2014)

ZnMCPPc

Spermine

(Ogbodu et al. 2015a)

ZnMAPc zinc monoamino phthalocyanine, ZnOPc zinc octacarboxy phthalocyanine, ZnMCPPc zinc monocarboxyphenoxy phthalocyanine

Fig. 29

Viability of melanoma cells incubated with SWCNT–FA, ZnMAPc–FA, and ZnMAPc–FA–SWCNT under irradiation (676 nm, 98 mW/cm2, 5 J/cm2)

[Taken from reference (Ogbodu et al. 2015b)]

Concerning ZnMAPc–spermine–SWCNT, the same authors decided to use a quartz lamp that can absorb sunlight from about 600 nm and beyond 1000 nm in order to investigate the PDT and PTT effects of ZnMAPc and SWCNT by varying different parameters, such as concentrations of ZnMCPPc, ZnMCPPc–spermine, or ZnMCPPc–spermine–SWCNT (from 5 to 40 μM) and irradiation time (5, 10, or 20 min) equivalent to an irradiation dose of 28–112 J/cm2. The best results were obtained at 40 μM concentration after 20-min irradiation. These results indicated that ZnMCPPc–spermine–SWCNT exhibited 5% cell viability but ZnMCPPc–spermine and ZnMCPPc showed 3% and 36%, respectively. ZnMCPPc–spermine has a better PDT effect compared to ZnMCPPc–spermine–SWCNT, as it possesses higher triplet and 1O2 quantum yield values, and no clear PTT effect of SWCNTs was observed (Fig. 30).
Fig. 30

Viability of MCF-7 breast cancer cells incubated with ZnMCPPc, ZnMCPPc–spermine, and ZnMCPPc–spermine–SWCNT at 40 μM concentration under irradiation (600–1000 nm, 93 mW/cm2, 112 J/cm2) for 20 min

[Taken from reference (Ogbodu et al. 2015a)]

Also in respect of SWCNTs, Safar et al. (2015) wished to combine chirality-enriched (6,5) single-walled carbon nanotubes (E-SWCNTs) and some porphyrins for estimating the potential PDT effect of these new hybrid systems. To achieve this goal, meso-tetrakis(4-pyridyl)porphyrin tosylate salt (H2TM4PyP (OTs)4, POR) and its myristyl analogue meso-tetrakis(N-myristyl-4-pyridinium)porphyrin tosylate salt (H2TMy4PyP (OTs)4, MYR) were chosen. Commercial Verteporfin (VER) was used as the reference. After studying the optical absorption of porphyrins and E-SWCNT (Table 6), the production of 1O2 for each hybrid system was evaluated using a white 5-LED lamp with a yellow or red filter (wavelength = 570 and 630 nm, respectively) or 940 nm. The authors observed that E-SWCNT alone can produce 1O2, involving very likely a direct energy transfer from E-SWCNT excitons to dissolved oxygen, but less than the hybrid systems. Furthermore, it has been shown in some cases that the hybrid systems have a better 1O2 production efficiency that the free porphyrins in the therapeutic window.
Table 6

Optical absorption of porphyrins and E-SWCNT

Compoundsa

Absorption bands (nm)b

POR

521, 556, 587, and 641

MYR

530 and 570

VER (commercial, reference)

575, 630, and 695

E-SWCNT

572 and 992c

POR meso-tetrakis(4-pyridyl)porphyrin tosylate salt, MYR meso-tetrakis(N-myristyl-4-pyridinium)porphyrin tosylate salt, VER verteporfin, E-SWCNT chirality-enriched (6,5) single-walled carbon nanotube

aPorphyrin aqueous solutions at 55 μM and aqueous suspension of E-SWCNT

bFor all porphyrins, another weak band can be observed from 900 to 1000 nm

cBands attributed to E22 and E11 optical transitions (Weisman and Bachilo 2003)

PDT/PTT applications

Some research teams worked on the use of photothermal effect of PS–graphene nanocomposites for the development of new theranostic nanoplatforms by combining PDT and PTT (Yang et al. 2010) to improve the efficacy against cancer.

Jiang and co-workers synthesized two new PS nanocarriers with a dual phototherapy effect (PDT/PTT) in one sonication step by coating tetrasulfonic acid tetrasodium salt copper phthalocyanine (TSCuPc) onto graphene sheets (GR) (2014b) and single-walled carbon nanohorns (SWNHs) (2014a) via ππ interactions. The loading efficiencies of TSCuPc were 27 and 38 wt% for GR–TSCuPc and SWNHs–TSCuPc nanohybrids, respectively. Both nanohybrid systems produce ROS, such as superoxide radical anion (O 2 ·‒ ) and hydroxyl radical (OH·), and their in vitro dual phototherapeutic effects (PDT/PTT) at the TSCuPc equivalent of 10 μg/mL using human cervical cancer HeLa cells were highlighted using a single wavelength (laser irradiation at 650 nm, 3 W/cm2 for 5 min) (Fig. 31).
Fig. 31

Viability of HeLa cells incubated with free TSCuPc, GR–TSCuPc, and SWNHs–TSCuPc nanohybrids (650 nm, 3 W/cm2)

[Taken from references (Jiang et al. 2014a, b)]

Gollavelli and Ling (2014) used a graphene derivative loaded with a PS by ππ stacking interactions in order to develop a new theranostic nanoplatform combining phototherapy (PDT and/or PTT) and imaging for cancer treatment and detection. Water-dispersible magnetic and fluorescent graphene NPs (MFG) and hydrophobic silicon napthalocyanine bis(trihexylsilyloxide) (SiNc4) as PS were chosen to achieve their goals (MFG size ≈ 40 nm, loading efficiency of PS 8.5 wt%). The Magnetic Resonance Imaging (MRI) measurements and the in vitro phototherapy study (PDT and PTT) were conducted on human cervical cancer HeLa cells (Fig. 32). The authors proved that MGF–SiNc4 was well internalized in HeLa, and T2-weighted MRI measurements revealed a great luminescence image and T2-weighted MRI contrast due to the fluorescence and superparamagnetic properties of MFG. It should be noted that MFG and SiNc4 can together absorb ≈ 775 nm light and it was demonstrated that a dual phototherapy effect (PDT and PTT) is possible to kill cells using an inexpensive single light source (tungsten halogen lamp equipped with a long pass filter capable of providing a light wavelength range of 750–1380 nm and delivers a power of 0.3 W/cm2 for 1 h). This experiment indicated a cancer cell-killing efficacy of ≈ 97.9% (PDT ≈ 64.7% and PTT ≈ 33.2%).
Fig. 32

Comparative cell viabilities by MTT assay of HeLa cells treated with different concentrations of SiNc4/MFG–SiNc4 under dark/photoirradiation conditions (750–1380 nm, 0.3 W/cm2, 1 h)

[Taken from reference (Gollavelli and Ling 2014)]

Graphene oxide

PDT applications

Dong et al. (2010) described the use of methoxy-poly(ethylene glycol)-conjugated nano-graphene oxide (NGO–mPEG) as a potential PS nanocarrier for anticancer PDT. Hydrophilic mPEG was conjugated to the NGO for increasing the solubility and stability of NGO in cell culture media. The authors found that the structure of NGO appeared like single-layer sheets with size down to 200 nm and thickness of about 2–3 nm and the cytotoxicity of NGO–mPEG towards human breast cancer MCF-7 cells was negligible. ZnPc as PS was loaded onto NGO–mPEG by ππ stacking and hydrophobic interactions (loading efficiency 14 wt%) to evaluate the in vitro photodynamic effect of NGO–mPEG/ZnPc. Human MCF-7 breast cancer cells were treated by different concentrations of NGO–mPEG/ZnPc for 24 h followed by an exposition to the UV band-path filtered Xe light irradiation for 10 min (60 J/cm2). Without light irradiation, the authors observed a cell viability of > 85% and, with irradiation, this value decreases from about 80 to 60% when the concentration was increased from 3.8 to 60 mg/L.

Wojtoniszak et al. (2013) showed that GO loaded with methylene blue (MB) as a PS by adsorption had a much higher 1O2 generation capacity than graphene after irradiation with 785-nm laser. They concluded that MB–GO could be used as a potential PS delivery system in PDT. No in vitro and in vivo studies have been conducted yet.

Miao et al. (2013) demonstrate that polyethylene glycol-grafted graphene oxide (pGO) nanosheets can be employed as the multimodal nanocarrier to co-deliver a PS Ce6 and Dox to induce synergystic photodynamic anticancer effect. The PEGylation of pGO is necessary to increase aqueous stability of pGO. Ce6 and Dox were co-loaded onto pGO nanosheets by ππ stacking and hydrophobic interactions (loading efficiencies 51.9 ± 5.1 and 61.7 ± 4.4 wt%, respectively) to form multimodal nanophysisorplexes (Ce6/Dox/pGO) with a size of 148.0 ± 18.0 nm. The in vitro cytotoxicity of GO and pGO nanosheets towards murine SCC7 squamous carcinoma cells was evaluated after treatment with a concentration of 40 μg/mL and the cell viability is around 90% for both. Conversely, the in vivo cytotoxicity, after treating mice by intravenous bolus injection of nanosheets at 80 mg/kg dose, showed no cytotoxicity for pGO nanosheets compared to the 10% survival rate for GO nanosheets. The authors proved by in vivo and in vitro studies (irradiation with 660-nm LED with a luminous intensity of 8000 mCd for 30 min) that the co-delivery of Ce6 and Dox by the pGO nanosheets induces a synergistic photodynamic anticancer effect and the best result was obtained at a Dox–Ce6 molar ratio of 1:2.

As did Dong and co-workers (2010), Zeng et al. (2015) also synthesized PEGylated nano-graphene oxide (NGO–PEG). The PEG-amine was covalently attached to NGO sheets for the dispersibility improvement of NGO in physiological conditions. The size of NGO–PEG is around 20–40 nm with a thickness ≈ 1.4 nm. The loading of Ce6 onto NGO–PEG by ππ stacking and hydrophobic interactions (loading efficiency ≈ 13 wt% at the feeding concentration of 2 mM) and in vitro PDT study (HeLa cells, laser irradiation 660 nm, 0.2 W/cm2 for 5 min) showed that NGO–PEG can be used as a PS nanocarrier. Furthermore, when coupled to branched polyethylenimine (BPEI) the resulting positively charged NGO–PEG–BPEI showed a better cellular uptake by HeLa cells and the loading ratio of Ce6 reached a value of 26 wt%. For the cellular uptake by HeLa cells, cytometric analysis, confocal microscopy, and fluorescence experiments were carried out. Figure 33a shows the viability of HeLa cells after light irradiation by 662-nm laser at a power density of 0.2 W/cm2 for 5 min and Fig. 33b shows the changes of Ce6 fluorescence intensity in cells as a function of incubation time. It can be noted that the mean fluorescence intensity of Ce6 in the NGO–PEG–BPEI–Ce6 system was 2.6-fold higher than that in NGO–PEG–Ce6 and 30-fold better than that in the free Ce6 system. This preliminary study indicated that NGO–PEG–BPEI–Ce6 could target the delivery of Ce6 into lysosome.
Fig. 33

a Viability of HeLa cells treated with free Ce6, NGO–PEG–Ce6, and NGO–PEG–BPEI–Ce6 at different concentrations of Ce6. b Ce6 fluorescence intensity in HeLa cells treated with Ce6, NGO–PEG–Ce6, and NGO–PEG–BPEI–Ce6 for various times

[Taken from reference (Miao et al. 2013)]

Yang et al. (2012) described a scaffold for PDT and drug delivery in which GO is the carrier, folic acid-modified cyclodextrin (FA-βCD) is a targeting agent, Dox is the drug, and adamantanyl porphyrin (AdaTPP) is a linker. The assembly of the nanocomposite resulted from successive mixings of GO, AdaTPP, and Dox to form GO–Dox/AdaTPP, then with FA-βCD by strong hydrophobic interaction between the CD cavity and adamantane moiety. The resulting assembly 1/2/Dox/GO showed no cytotoxicity towards normal cells over a 1-day period but induced tumor growth inhibition in vivo in HeLa-bearing BALB/c nude mice as illustrated in Fig. 34.
Fig. 34

Tumor growth curves for BALB/c nude mice with HeLa cancer cells

[Taken from reference (Yang et al. 2012)]

Yan et al. (2014) reported the regulation of 1O2 production probe using the binding properties of an aptamer (AP). The concept of this molecular beacon [for a review, see (Verhille et al. 2010)] is based on a non-covalent binding of a cDNA aptamer–Ce6 (AP–Ce6) moiety with GO as an efficient fluorescence and SOG (singlet oxygen generation) quenching probe. In the absence of a target, the PS is not active due its close proximity to GO. Once the AP hybridizes with the target, the 1O2 production is restored (Fig. 35).
Fig. 35

Concept of photomolecular beacon

[Taken from reference (Yan et al. 2014)]

Adenosine-5′-triphosphate (ATP), which is overexpressed on the extracellular surface of cancer cells besides the mitochondrial matrix, was used as a proof-of concept target molecule. The graphene-based GO/AP–Ce6 was prepared by mixing GO and AP–Ce6 and exhibited a size of 80 nm and a thickness of about 1.2 nm. The quenching by graphene is clearly evidenced in Fig. 36a, and it can be noted that the presence of ATP as a target restored the ability of Ce6 to produce 1O2 owing to stronger interactions between ATP and AP–Ce6 than those of GO and the PS. In human HepG2 cells, 1O2 was detected using DCFH-DA (2′,7′-dichlorodihydrofluorescein diacetate) method and the results evidenced the restoration of 1O2 production in the presence of ATP (Fig. 36b). These results are comforted by cell viability after light irradiation at 404 nm for 10 min (Fig. 36c).
Fig. 36

a The Ce6 and SOSG signal readouts after irradiation condition (404 nm, 10 min). b DCF fluorescence intensity in HepG2 cells. c Cellular viability of HepG2 cells treated with light

[Taken from reference (Yan et al. 2014)]

A targeted ligand is often required to provide a better selectivity of the PS. Within this scope, some teams developed targeted nanocarrier systems for the PS delivery.

Huang and co-workers (2011) prepared GO as single-layer sheet (sheet-like shapes) with a thickness of about 1.2 nm covalently linked to folic acid (FA). The PS (Ce6) was then loaded onto FA–GO (loading efficiency ≈ 80 wt%) via hydrophobic interactions and ππ stacking. The in vitro cytotoxicity of FA–GO and FA–GO–Ce6 was measured after 24-h incubation with MGC803 cells and showed that GO–FA does not have any dark toxicity and the dark cytotoxicity of FA–GO–Ce6 is dependent upon Ce6 concentration. The intracellular distribution study revealed a higher accumulation of Ce6 inside the tumor. The in vitro PDT effect was studied after the exposure of MGC803 cells to FA–GO–Ce6 at different ratios (FA–GO:Ce6, 10:1 to 1:1 wt%) followed by irradiation with a He–Ne laser (632.8 nm, ≈ 30 mW/cm2) for 10 min. Without irradiation, cell viability above 80% was observed and after light exposure only ≈ 10% of cell viability was detected for 1:1 and 2:1 ratios.

The same team (Huang et al. 2015) described the preparation of reduced graphene oxide (rGO) nanosheets covalently linked to polyvinylpyrrolidone (PVP). PVP was used for increasing aqueous dispersibility and biocompatibility of rGO. The rGO–PVP shows a sheet-like shape with PVP layers of thickness ≈ 0.85 nm on each side of the 0.96 ± 0.05-nm-thick rGO layers (total thickness for rGO–PVP 2.81 ± 0.18 nm). The ACDCRGDCFCG peptide (RGD4C), used as vectors for αvβ3 integrin-targeted delivery of PSs, was covalently anchored to rGO–PVP and the resulting rGO–PVP–RGD was loaded with Ce6 by hydrophobic interactions and ππ stacking (loading efficiency ≈ 80 wt%). No dark cytotoxicity of rGO–PVP and rGO–PVP–RGD on MGC803 cells was observed in the concentration range of 0–500 μg/mL (cell viability higher than 95%). The authors also observed that rGO–PVP–RGD–Ce6 induced a better PDT effect on cells as compared to free Ce6 and rGO–PVP–Ce6 at all tested concentrations (0–50 M Ce6, i.e., 0.6–30 μg/mL Ce6) after laser irradiation (671 nm, 30 mW/cm2 for 3 min) (Fig. 37). These results demonstrated the active targeting ability of RGD. The 1O2 generation from rGO–PVP–RGD–Ce6 has been detected by measuring the fluorescence signal of singlet oxygen sensor green (SOSG).
Fig. 37

Viability of MGC803 cells treated with different concentrations of Ce6, rGO–PVP–Ce6 or rGO–PVP–RGD–Ce6 for 24 h at 37 °C without or with irradiation (671 nm, 30 mW/cm2)

[Taken from reference (Huang et al. 2015)]

Li et al. (2013) covalently attached hyaluronic acid (HA) onto the surface of GO nanosheets in order to target cancer cells with overexpressed HA receptors. The hydrodynamic diameter of GO nanosheets is 59.3 nm and the average diameter of HA–GO nanocarrier is 78.1 nm. Ce6 was loaded onto HA–GO via ππ stacking and/or hydrophobic interactions (loading efficiency 115 wt% at the feeding concentration of 1.5 mg/mL). The in vitro phototoxicity study (laser irradiation 670 nm, 1.8 J/cm2) of HA–GO/Ce6 nanohybrids towards human cervical cancer HeLa cells showed a photodynamic efficacy ten times greater than free Ce6 (IC50 shifted from 1 to 0.1 μg/mL).

Xu et al. (2015) described a dual-targeting nanosystem comprising a modified nano-graphene oxide (NGO) as the carrier and a PS (5-(p-(4-trimethylammonium)-butoxyphenyl)-10,15,20-triphenylporphyrin bromide abbreviated MitoTPP). The NGO nanocomposite was modified as follows: Firstly, 4-arm PEG-amine was covalently coupled as described by Li et al. (2013) to enhance dispersibility and biocompatibility, and secondly folic acid (FA) NHS ester was grafted on NGO–PEG to give the modified NGO–PEG–FA composite. Finally, an overnight mixing of NGO–PEG–FA and MitoTPP afforded the desired nanosystem NGO–PEG–FA/MitoTPP (loading of MitoTPP was estimated to be 37.2 wt%). The in vitro release of MitoTPP was strongly dependent on pH. Due to the non-ionized carboxyl groups in NGO at pH 5.0, the electrostatic attraction is much weaker and promotes the release of MitoTPP from NGO and permits to escape from the acidic endosome/lysosome compartments and then diffuse into mitochondria. Confocal microscopy showed that the intracellular localization of MitoTPP was found to be mitochondria. 1O2 generation was observed using ABDA (9,10-anthracenediyl-bis(methylene)dimalonic acid) indicator at pH 7.4 and 5.0 under irradiation and over different periods. While the absorbance of ABDA did not change at pH 7.4 for 1 h, the one at pH 5.0 dramatically decreased within the initial 15-min irradiation, indicating that MitoTPP can induce 1O2 after being released from NGO. The presence of FA in the nanocomposite induced a much brighter fluorescence than with NGO–PEG/MitoTPP demonstrating dual targeting. The phototoxicity caused by PDT is presented in Fig. 38 which clearly shows the greater effectiveness of this double targeting after 30 min of light irradiation (650 nm, 10 mW/cm2).
Fig. 38

Viability of HeLa cells after treatment with NGO–PEG/MitoTPP in the presence/absence of FA and light (650 nm, 10 mW/cm2, 30 min)

[Taken from reference (Xu et al. 2015)]

Zhou and colleagues (2015) worked on the development of a photosensitive and magnetically targeted PS delivery system by dispersing in a uniform size the Fe3O4 magnetic NPs on the GO surface by co-precipitation method. The thickness of the single-layer sheet was about 0.8 nm and the saturation magnetization value of the resulting GO–Fe3O4 nanocomposite was about 15 emu/g, preventing any Fe3O4 aggregation on GO. Hematoporphyrin (HP) was loaded onto GO–Fe3O4 by hydrophobic interactions and ππ stacking (loading efficiency 23.6 wt%). The authors determined that GO–Fe3O4 produces 1O2 but in smaller quantities compared to HP alone (63.4% of the value obtained with free HP), which is in agreement with the literature (Tian et al. 2011). The in vitro study on human cervical cancer HeLa cells highlighted the fact that the IC50 value of GO–Fe3O4–HP decreased from 189.24 μg/mL (dark cytotoxicity) to 10.12 μg/mL after incubating the cells with GO–Fe3O4–HP for 24 h followed by laser irradiation at 671 nm (0.1 W/cm2) for 5 min and continued incubation for 72 h. These results clearly demonstrate that the magnetic GO–Fe3O4 nanocomposite could be used as the tumor-targeted PS delivery system under proper external magnetic field and as a photosensitive PDT agent under laser irradiation at 671 nm to produce 1O2.

Recently, Chang et al. (2015) described a new concept using near-infrared (NIR) irradiation as a stimulus for the formation of the hydrogel shells inducing cell death. The developed hydrogel precursor (rGO/AE/AuNPs) was composed of reduced graphene oxide (rGO), amaranth extract (AE), and gold nanoparticles (AuNPs). AuNPs and rGO were used for their PTT properties and ability to speed up the 1O2 generation. AE was used as a PS (due to the chlorophyll derivatives contained in the extract) and as a cross-linking agent. The authors showed that the hydrogel precursor was initially in the form of a viscous oil, but a rapid hydrogel formation was observed upon 10-min NIR irradiation. This hydrogel formation can be ascribed to several interactions between the various constituents of the hydrogel precursor, i.e., excess of AE inducing reduction of GO to rGO, formation of dewatered rGO sheets caused by an increase in the temperature of precursor under NIR irradiation, improvement of the ππ stacking and hydrophobic interactions among rGO sheets, and finally electrostatic attraction between positively charged Au NPs and negatively charged GO sheets. In vitro studies on Chinese hamster ovary (CHO) and HeLa cancerous cells showed an in situ hydrogel shell formation on cells after laser irradiation (600 nm, 2 W/cm2 for 10 min), which led to an enrichment of PS and PTT agents around the tumor cells resulting in cell death via a dual PDT/PTT treatment with minimal side effects (Fig. 39).
Fig. 39

Viability of HeLa and CHO cells treated with AE, rGO/AE, and rGO/AE/AuNPs in the dark or after light irradiation (600 nm, 2 W/cm2 for 10 min)

[Taken from reference (Chang et al. 2015)]

The same year, Rong and co-workers (2014) used polyethylene glycol-functionalized graphene oxide (PEG–GO) as a PS delivery system. PEG–GO was loaded with 2-(1-hexyloxyethyl)-2-devinyl pyropheophorbide-alpha (HPPH, Photochlor®) as a PS (loading efficiency 131 wt%) by supramolecular ππ stacking. The PEG–GO system was of about 50 nm and has a thickness of around 1.5 nm, which reaches up to 2 nm after HPPH loading (Fig. 40).
Fig. 40

Schematic structure of the GO–PEG–HHPH system

[Taken from reference (Rong et al. 2014)]

The in vitro PDT studies of GO–PEG–HPPH, GO–PEG, and HPPH alone towards murine breast cancer 4T1 cells were performed after incubation with GO–PEG–HPPH (1 μm equivalent of HPPH and 0.49 μg/mL of GO–PEG) for 24 h followed by laser irradiation at 671 nm (4 mW/cm2) for 3 min. No dark cytotoxicity was observed, and after irradiation GO–PEG–HPPH caused a greater cell death than HPPH alone (Fig. 41a). The in vivo HPPH delivery and PDT effects of GO–PEG–HPPH and free HPPH were studied in 4T1 tumor-bearing mice with both fluorescence and PET (positron emission tomography) imaging. While there was a reduction of the generation of 1O2 by GO–PEG–HPPH compared to the free HPPH, a better accumulation of HPPH into the tumor region was observed. The in vivo PDT study was carried out after an i.v. injection of GO–PEG–HPPH or free HPPH ([HPPH] = 1 mg/kg in both cases) followed by laser irradiation at 24 h post injection (671 nm, 75 mW/cm2 for 20 min). A marked improvement in average life expectancy has also been observed (35% after 60 days). Subsequently, the volume of tumors in the GO–PEG–HPPH-treated mice decreased in the first 2 days and remained unchanged for at least 14 days (Fig. 41b).
Fig. 41

a Viability of 4T1 cells incubated with various concentrations of free HPPH, GO–PEG, and GO–PEG–HPPH after irradiation at 671 nm (4 mW/cm2, 3 min). b Tumor growth curves of different groups of tumor-bearing mice after PDT treatment. The tumor volumes were normalized to their initial values

[Taken from reference (Rong et al. 2014)]

Cho et al. (2012) linked GO to Ce6 with disulfide bond (SS) to generate GO–SS–Ce6 system having an average hydrodynamic size of around 102.4 ± 15.2 nm and a homogeneous dispersion with 1–2 nm thickness, showing single- or double-layered graphene structures. Glutathione (GSH) or dithiothreitol (DTT) was used as a redox-responsive cleavable disulfide linker. These compounds did not present any fluorescence and phototoxic properties, even upon light irradiation. The UV/Vis and fluorescence spectroscopy studies demonstrated the quenching effect of GO on the fluorescence yield of Ce6 and the cleavage of the disulfide bonds. The fluorescence intensity of GO–SS–Ce6 was ninefold greater after incubation in 1 mM DTT solution for 3 h. The authors also studied the 1O2 generation of several solutions (free Ce6, GO–SS–Ce6, and GO–SS–Ce6 + 1 mM DTT) under CW laser beam irradiation (670 nm, 100 mW/cm2) and found that the simultaneous treatment of GO–SS–Ce6 by 1 mM DTT and laser irradiation produces a significant increase of 1O2 generation compared to the GO–SS–Ce6 solution alone, reaching around the same level as the free Ce6 solution. The in vitro GSH-activatable fluorescence imaging and PDT studies of free Ce6 and GO–SS–Ce6 towards human lung cancer A549 cells (dark incubation for 24 h followed by diode laser irradiation at 670 nm, 20 J/cm2) showed effective cellular internalization and preferential accumulation of Ce6 in the cancer cells, especially in the lysosomes (Fig. 42).
Fig. 42

In vitro PDT efficacy on A549 cells of free Ce6 and GO–SS–Ce6 system under dark or light irradiation conditions (670 nm, 20 J/cm2)

[Taken from reference (Cho and Choi 2012)]

Tian et al. (2015) synthesized GO coupled to FA, a PS, and to an enzyme-responsive substrate (peptide) to control the selective release of PS at specific sites. The folate-based conjugate and the PS-labeled peptide substrate consist of 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[folate(poly ethylene glycol)-2000] (DSPE-PEG2000-FA) and Ce6-GRRGKGGFFFF (Ce6-Pep), respectively, and were loaded onto GO by ππ and hydrophobic interactions. The peptide GRRGKGGFFFF is known to be a cathepsin B (CaB)-activatable substrate with a specific cleavage of the RR peptide bond. GO sheets have a size less than 100 nm and a dispersion with 0.4 nm thickness, showing a single-layered graphene structure. The successive loading of Ce6-Pep and DSPE-PEG2000-FA was observed with the increase of thickness, rising from 0.4 to 0.7 then to 1.2 nm, respectively. The Ce6-Pep loading of Ce6-Pep/DSPE-PEG2000-FA/GO nanoprobe was 35 wt%. The fluorescence intensity of Ce6-Pep/GO increased by a factor of 18 after the addition of CaB, the fluorescence of Ce6-Pep was not restored by adding Cathepsins D or L with Ce6-Pep/GO. Lysosome-targeting and CaB-activatable fluorescence nanoprobes for imaging cancer cells have been shown with in vitro studies using FR-positive HeLa or KB cells and FR-negative HaCaT or A549 cells. Other in vitro and in vivo studies (HaCaT and/or HeLa cells) were also performed to demonstrate the PDT effect (660 nm, 250 mW/cm2, 50 J/cm2 during 200 s) and in vivo tumor imaging.

PDT and PTT applications

Tian and co-workers (2011) combined the PTT effect and PDT using PEGylated graphene oxide (GO-PEG) loaded with Ce6 via supramolecular ππ stacking. The size of the NPs was down to 50 nm and the thickness was about 1 nm. The maximal Ce6 loading capacity of GO-PEG was 15 wt% at the feeding concentration of 3 mM. The in vitro study was carried out after the exposure of KB cells to GO-PEG–Ce6 followed by different possible laser irradiations: (i) at 660 nm (15 J/cm2) for 5 min to test the PDT effect, (ii) at 808 nm (0.3 W/cm2, 360 J/cm2, 20 min) to test the PTT effect, or (iii) both with PTT irradiation before PDT treatment. Despite a reduction of the 1O2 generation for GO-PEG–Ce6 compared to free Ce6, the photodynamic effect was significantly increased thanks to a synergistic combination of PDT and PTT effects (Fig. 43).
Fig. 43

a Schematic structure of GO-PEG–Ce6. b Viability of KB cells under different light irradiations (Ce6 concentration: 5 μM)

[Taken from reference (Tian et al. 2011)]

Cao and co-workers (2016) used the same GO-PEG–Ce6 NPs to apply tandem PDT/PTT treatment on the murine breast cancer cell line 4T1. The authors obtained similar results to Tian et al. (vide supra). Interestingly, after PTT treatment they observed a greater tumor apparent diffusion coefficient (ADC) value in diffusion-weighted imaging (DWI) maps. Furthermore, after PDT treatment the apparent transverse relaxation rate (R 2*) was enhanced and allowed blood oxygenation level-dependent magnetic resonance imaging (BOLD MRI). They clearly demonstrated that the tandem DWI and BOLD MRI after PTT/PDT treatment is a very promising tool for monitoring and prognosis.

Sahu et al. (2013) developed nano-graphene oxide (NGO) coated with pluronic block copolymer to stabilize the NPs in biological fluids. The hydrodynamic size of NGO was 38.4 ± 3.1 nm, while it was 40.6 ± 2.8 nm after coating with pluronic. Methylene blue (MB) was loaded onto the coated NGO (NGO–MB) via electrostatic interactions. The maximal MB loading capacity was 22.7 ± 0.6 wt% at the feeding ratio of 70:30 (NGO/MB) with a hydrodynamic size of 43.5 ± 5.1 nm and large aggregates were observed when the feeding ratio is 50:50. The in vitro study (PDT irradiation: CW laser at 655 nm for 3 min, PTT irradiation: NIR laser at 808 nm for 3 min or dual treatment) was performed with human cervical cancer HeLa cells and mouse normal fibroblast cells (NIH/3T3) and the in vivo study (PDT irradiation: CW laser at 650 nm, ≈ 150 mW/cm2, for 10 min; PTT irradiation: NIR laser at 808 nm, 2 W/cm2 for 3 min) with HeLa cells. NGO–MB generates less 1O2 than free MB but, as seen previously, the photodynamic effect is dramatically increased in vitro with dual treatment (Fig. 44a). Concerning the in vivo photodynamic effect on mice, the PDT treatment showed a small decrease in tumor growth, while it has been significantly reduced by the PTT treatment (incomplete tumor ablation) (Fig. 44b). The combination of PDT/PTT treatments revealed a complete regression of tumor even after 15 days of treatment.
Fig. 44

a In vitro cytotoxicity effect of MB, NGO, and NGO–MB in NIH/3T3 and HeLa cells after PDT, PTT, and PDT + PTT treatments. b PTT treatment effect on the tumor tissue before (left) and after 1-day irradiation (right)

[Reused with permission from reference (Sahu et al. 2013)]

In two recent publications (Yan et al. 2015a, b), Chen’s team described new nanocomposites made from a PEGylated graphene oxide (PEG–GO) loaded by sinoporphyrin sodium (DVDMS, Fig. 45a). The DVDMS loading capacity reaches a maximum of 201.2 wt% in the resulting GO-PEG–DVDMS nanodevice. Interestingly, the fluorescence intensities of GO-PEG–DVDMS are 3–8 times higher than that of the free DVDMS. This can be due to the two sterically hindered porphyrin rings in the PS, one being involved in the ππ interactions with GO, the other being hanging out and responsible for this phenomenon. 1O2 generation of GO-PEG–DVDMS is slightly lower than that of DVDMS at the same concentration. In the first paper (Yan et al. 2015a), the authors showed a slight dose-dependent in vitro cytotoxicity to U87MG cells in the range of 0.3–5 mg/mL of DVDMS (Fig. 45b). Concerning the PDT efficiency, they found that GO-PEG–DVDMS induced quasi-total cell death at the dose of 5 mg/mL of DVDMS upon 630-nm laser irradiation, after 24-h incubation. The in vivo PDT experiments were performed in U87MG tumor-bearing mice model (630 nm at a dose of 50 J) and the GO-PEG–DVDMS laser group showed a life span longer than 30 days as compared to 22 days for the DVDMS laser group.
Fig. 45

a Chemical structure of DVDMS. b Viability of U87MG cells incubated with various concentrations of free DVDMS, GO-PEG, or GO-PEG-DVDMS after irradiation by 630-nm laser (2 J)

[Taken from references (Yan et al. 2015a, b)]

In the second paper (Yan et al. 2015b), they studied the dual-modality imaging-guided synergistic PDT/PTT therapies on PC9 cells in vitro and PC9 tumor-bearing mice in vivo. They noticed a high accumulation of GO-PEG–DVDMS in the tumor tissues due to EPR effect. 24 h post injection, PTT alone (808 nm, 1 W/cm2 for 10 min) induced an increase of tumor temperature up to 57 °C, while that of the healthy tissues only reached 32 °C. The synergistic effect of PDT/PTT is shown in Fig. 46.
Fig. 46

Effect of irradiation conditions (PDT and/or PTT) on HeLa cell viability using free DVDMS, GO-PEG, or GO-PEG–DVDMS (mGO-PEG:mDVDMS = 1:2, GO-PEG concentration = 3 μg/mL). a PDT effect (630 nm, 2 J/well). b PTT effect (808 nm, 1 W/cm2, 3 min/well). c Synergetic PDT/PTT effect

[Taken from reference (Yan et al. 2015b)]

Wang et al. (2013) developed a new concept of NIR imaging and PTT/PDT therapy. Upconversion nanoparticles (UCNPs) were obtained as previously described (Bogdan et al. 2011) and treated by poly(allylamine) as a surface coating agent. The modified UCNPs were then covalently coupled to NGO via carbodiimide cross-linking. The UCNPs–NGO was mixed with ZnPc to give the final composition (Fig. 47) with a ZnPc loading amount of 11 wt% and an average diameter of 40 nm as assessed by TEM.
Fig. 47

Schematic illustration of UCNPs–NGO/ZnPc as a multifunctional theranostic nanoplatform for cancer treatment

[Taken from reference (Wang et al. 2013)]

The 1O2 production (DPBF (1,3-diphenylisobenzofuran) method) of UCNPs–NGO/ZnPc was lower than that of ZnPc alone due to the presence of NGO but was still 60%. Furthermore, the good biocompatibility and the low cytotoxicity allowed using these NPs for PDT treatment. Figure 48 shows the PDT and PTT effects after irradiation. It can be seen clearly that the PDT effect (green) is the main phenomenon as compared to the PTT effect (red), but the combined PDT/PTT effect reduced the viability of HeLa cells to 15% (blue).
Fig. 48

In vitro cell viability assay in HeLa cells of UCNPs–NGO/ZnPc at different concentrations without irradiation (black) and after PDT (green), PTT (red), or combined PDT/PTT (blue) treatments

[Taken from reference (Wang et al. 2013)]

One year later, the same team (Cho et al. 2013) described the elaboration of GO–HA–Ce6 nanoplatform, as was the case with Li et al. (2013), but this time based on a covalently linked hyaluronic acid–chlorin e6 (HA–Ce6) loaded onto the surface of nanosized GO via ππ and hydrophobic interactions (average hydrodynamic size 441.1 ± 48.8 nm). The objective of this work was to develop an enzyme-activatable theranostic agent using HA, which is known to preferentially accumulate in the extracellular matrix and to be degraded quickly in the presence of hyaluronidase (HAdase) enzyme. The quenching effect of GO on the fluorescence yield of Ce6 and the cleavage of the glycosidic bonds were demonstrated by comparing the fluorescence emission spectra of GO, HA–Ce6, and GO–HA–Ce6 at a same Ce6 concentration. When GO–HA–Ce6 is treated with HAdase (800 U/mL), the fluorescence signal increased by a factor of 5, indicating a Ce6 release of approximately 21% from the GO surface. The in vitro studies (Fig. 49) of GO–HA–Ce6 were performed with human lung cancer A549 cells and a synergistic phototherapy effect (PDT: CW laser beam irradiation, 670 nm, 50 mW/cm2, 4 J/cm2 and PTT: 810 nm, 4 W/cm2, 250 J/cm2) was observed, making it an interesting HAdase-activable theranostic agent combining phototherapy (PDT/PTT) and activatable fluorescence imaging-guided treatment for cancer tumors.
Fig. 49

In vitro cell viability assay in A549 cells of free Ce6, HA–Ce6, and GO–HA–Ce6 at the same Ce6 concentration (1.8 μM equivalent) without irradiation (black) and after PDT (670 nm, red), PTT (810 nm, purple), or combined PDT/PTT (670 and 810 nm, yellow) treatments

[Taken from reference (Cho et al. 2013)]

Taratula and co-workers (2015) described a new targeted graphene-based nanoplatform combining phototherapy (PDT/PTT) and imaging-guided tumor treatment for ovarian cancer. For the first time, the monosubstituted silicon phthalocyanine Pc(OH)(mob) was loaded onto polypropylenimine generation 4 (PPIG4) dendrimer and the resulting adduct was covalently attached to low-oxygen graphene (LOGr) nanosheets through the amine functions of the dendrimer affording LOGr–Pc. Finally, the luteinizing hormone-releasing hormone (LHRH) peptide was grafted to give LOGr–Pc–LHRH nanoplatform. PEGylation and peptide were necessary to increase biocompatibility and to target LHRH receptors overexpressed on the membranes of both primary and metastatic ovarian cancer cells. The hydrodynamic diameter of LOGr–PC–LHRH was 78.3 ± 9.54 nm (≈ 15 and 62 nm for the LOGr and Pc–LHRH, respectively) and the Pc loading efficiency onto PPIG4 was approximately 20 wt%. The in vitro combination phototherapy effect (PDT/PTT) of the nanoplatform ([Pc] = 1.0–4.0 μg/mL and [LOGr] = 1.8–7.0 μg/mL) towards LHRH-positive A2780/AD ovarian cancer cells has been demonstrated using a single wavelength (laser diode irradiation at 690 nm, 0.3 W/cm2 for 15 min) to induce 1O2 generation by Pc and PTT effect by LOGr (Fig. 50). The in vivo NIR fluorescence imaging was also highlighted after administration of LOGr–Pc–LHRH in mice bearing A2780/AD tumor.
Fig. 50

In vitro cell viability assay in A2780/AD cells of LOGr–LHRH, Pc–LHRH, and LOGr–Pc–LHRH at different LOGr concentrations after combined PDT/PTT treatment (690 nm, 0.3 W/cm2, 15 min)

[Taken from reference (Taratula et al. 2015)]

In the same year, Kim and co-workers (2015) opted to use core and shell NPs (core@shell) to report a “one-pot synthesis” of a new theranostic nanoplatform combining Raman bioimaging and phototherapy (PDT/PTT). These core@shell NPs are composed of Au core and graphene oxide nanocolloid (GON) shells, onto which PEG and ZnPc have been grafted and loaded, respectively. The PEG was added to give a better colloidal stability in biological media and the PS was loaded onto Au@GON NPs via ππ interactions (loading efficiency 1.9 × 106 ZnPc/NP). The size of the Au@GON NPs, approximately spherical in shape, is 60 ± 15 nm with 2–3 nm GON shell thickness. The in vitro evaluation of Raman imaging and dual PDT/PTT effect of the resulting ZnPc–PEG–Au@GON NPs in human cervical cancer HeLa cells were investigated and the results demonstrated that these NPs can be intended to conduct Raman imaging and have a synergistic phototherapy effect (PDT: LED irradiation at 660 nm, 0.2 mW/cm2 for 10 min and PTT: laser irradiation at 808 nm, 0.67 W/cm2 for 20 min) with 1O2 generation (Fig. 51).
Fig. 51

In vitro cell viability assay in HeLa cells of free ZnPc, PEG–Au@GON NPs, and ZnPc–PEG–Au@GON NPs without irradiation (black) and after PDT (660 nm, 0.2 W/cm2, 10 min, blue), PTT (808 nm, 0.67 W/cm2, 20 min, red), or combined PDT/PTT (green) treatments

[Taken from reference (Kim et al. 2015)]

Graphene is a new material but is already called a new wonderful material thanks to many advantages. Its structure and physico-chemical properties make it an excellent candidate for different applications ranging from solar cells to cancer treatment. In the field of PDT, the first paper was published in 2010 and more than 35 papers have been published to date.

Thanks to its large surface area, it is possible to use it as an efficient PS carrier. Its ππ structure can easily bind to aromatic PS. Graphene presents also high dispersibility in water and good stability in biological media. We can notice that it is a very good conductor of heat and it can be used to perform both PDT and PTT. One of the disadvantages might be its size compared to small NPs, except nanorods.

One of the advantages of graphene oxide (GO) is its easy dispersibility in water and other organic solvents due to the presence of oxygen atoms. Moreover, it can be very easily functionalized and also one publication describes the covalent binding of Ce6 onto GO. Folic acid, hyaluronic acid, or peptides have already been successfully bound onto GO.

Few papers describe the use of reduced graphene oxide (rGO), which might be due to its tendency to aggregate. Table 7 below summarized the data available on the application of graphene NPs with grafted or encapsulated PSs in PDT and/or PTT.
Table 7

Application of graphene NPs in PDT and/or PTT

Type of NPs (size, nm)

PS (amount)

NPs–PS interactions

Irradiation conditions

Type of ROS

Cancer cell line

Ref.

In vitro

In vivo

Nanosheets (200)

ZnPc (14 wt%)

ππ stacking

Hydrophobic

UV band-path filtered Xe light, 60 J/cm2, 10 min

nd

MCF-7

Dong et al. (2010)

Nanosheets (nd)

MB (nd)

nd

Laser 785 nm

1O2

Wojtoniszak et al. (2013)

Nanosheets (148)

Ce6 (51.9 wt%)

ππ stacking

Hydrophobic

LED 660 nm, 8000 mCd, 30 min

nd

SCC7

SCC7 bearing mice

C3H/HeN mice

Miao et al. (2013)

Nanosheets (20–40)

Ce6 (26 wt%)

ππ stacking

Hydrophobic

Laser 660 nm, 0.2 W/cm2, 5 min

ROS

1O2

HeLa

Zeng et al. (2015)

Nanosheets (nd)

Ce6 (160 wt%)

ππ stacking

Laser 660 nm, 2 min

ROS

HeLa

Liu et al. (2015a)

Nanosheets (200)

ZnPc (60 wt%)

ππ stacking

Hydrophobic

Light 660 nm, 0.15 W/cm2, 10 min

1O2

HeLa

MCF-7

Wu et al. (2014)

Nanosheets (120)

MitoTPP (37.2 wt%)

π–π stacking

Electrostatic

LED 650 nm, 10 mW/cm2, 30 min

1O2

HeLa

Xu et al. (2015)

Nanosheets (nd)

HP (23.6 wt%)

ππ stacking

Hydrophobic

Laser 671 nm, 0.1 W/cm2, 5 min

1O2

HeLa

Zhou et al. (2015)

Nanosheets (300–400)

AdaTPP (nd)

ππ stacking

Visible light

ROS

HeLa

OCT-1

HeLa-bearing BALB/c nude mice

Yang et al. (2012)

Nanosheets (80)

AP-Ce6 (23.1 wt%)

ππ stacking

Light 650 nm, 50 mW/cm2, 20 min

1O2

HepG2

Yan et al. (2014)

Nanosheets (nd)

Ce6 (80 wt%)

ππ stacking

Hydrophobic

He–Ne laser 632.8 nm, 30 mW/cm2, 10 min

nd

MGC803

Huang et al. (2011)

Nanosheets (nd)

Ce6 (80 wt%)

ππ stacking

Hydrophobic

Laser 671 nm, 30 mW/cm2, 3 min

1O2

MGC803

Huang et al. (2015)

Nanosheets (78.1)

Ce6 (115 wt%)

ππ stacking

Hydrophobic

Laser 670 nm, 1.8 J/cm2

1O2

HeLa

Li et al. (2013)

Nanosheets (50)

Ce6 (15 wt%)

ππ stacking

Laser 660 nm, 15 J/cm2, 5 min (PDT); Laser 808 nm, 0.3 W/cm2, 360 J/cm2 (PTT)

1O2

KB

Tian et al. (2011)

Nanosheets (38.4)

MB (22.7 wt%)

Electrostatic

CW laser 650 nm, 0.15 W/cm2, 10 min (PDT) ; NIR laser 808 nm, 2 W/cm2, 3 min (PTT)

1O2

HeLa

NIH/3T3

HeLa

(Sahu et al. 2013)

Nanosheets (nd)

TSCuPc (27 wt%)

ππ stacking

Laser 650 nm, 3 W/cm2, 5 min

ROS

HeLa

Jiang et al. (2014b)

Nanorods (nd)

TSCuPc (38 wt%)

ππ stacking

Laser 650 nm, 3 W/cm2, 5 min

ROS

HeLa

Jiang et al. (2014a)

Nanosheets (20.5)

DVDMS (100 wt%)

ππ stacking

Laser 630 nm, 50 J (PDT); NIR laser 808 nm, 1 W/cm2, 10 min (PTT)

1O2

PC9

PC9 tumor-bearing mice

Yan et al. (2015a)

Nanosheets (50)

DVDMS (201.2 wt%)

ππ stacking

Hydrophobic

Laser 630 nm, 50 J

1O2

U87MG

U87MG tumor-bearing mice

Yan et al. (2015b)

Nanorods (1–5)

ZnMAPc (nd)

nd

Diode laser 676 nm, 98 mW/cm2, 5 J/cm2

1O2

A375

Ogbodu et al. (2013a, b, 2015b)

Nanorods (1–5)

ZnMAPc (nd)

nd

602 nm

1O2

Ogbodu et al. (2013b)

Nanorods (1–5)

ZnMCPPc (nd)

nd

Quartz lamp 600–1000 nm, 28–112 J/cm2, 5–20 min

1O2

MCF-7

Ogbodu et al. (2015a)

Nanorods (1–5)

ZnOCPc (nd)

nd

610 nm

1O2

Ogbodu and Nyokong (2014)

Nanorods (nd)

POR, MYR (nd)

ππ stacking

LED lamp 570 nm (yellow filter), 630 nm (red filter) or 940 nm

1O2

Safar et al. (2015)

Nanorods (nd)

Ce6 (11.3 wt%)

ππ stacking

Laser 630 nm, 0.15 W/cm2, 10 min

nd

HeLa

NIH/3T3

Xiao et al. (2012)

Nanosheets (40)

ZnPc (11 wt%)

ππ stacking

Laser 630 nm, 50 mW/cm2, 10 min (PDT); NIR laser 808 nm, 2 W/cm2, 10 min (PTT)

1O2

HeLa

KB

Wang et al. (2013)

Hydrogel shells (35)

AE (nd)

ππ stacking

Hydrophobic

Laser 600 nm, 0.2 W/cm2, 10 min

1O2

HeLa

CHO

Chang et al. (2015)

nd (40)

SiNc4 (8.5 wt%)

ππ stacking

Halogen lamp 775 nm, 0.3 W/cm2, 60 min

ROS

1O2

HeLa

Gollavelli and Ling (2014)

Nanosheets (50)

HPPH (131 wt%)

ππ stacking

Laser 671 nm, 2-8 mW/cm2, 3 min (in vitro) and 75 mW/cm2, 20 min (in vivo)

1O2

4T1

4T1-bearing mice

Rong et al. (2014)

Nanosheets (102.4)

Ce6 (nd)

Grafted with disulfide bond (SS)

CW laser beam 670 nm, 0.1 W/cm2, 20 J/cm2

1O2

A549

Cho and Choi (2012)

Nanosheets (441.1)

Ce6 (nd)

Hydrophobic

CW laser beam 670 nm, 0.1 W/cm2, 20 J/cm2

1O2

A549

Cho et al. (2013)

Nanosheets (100)

Ce6-Pep (35 wt%)

ππ stacking

Hydrophobic

Laser 660 nm, 0.25 W/cm2, 200 s

1O2

KB

A549

HeLa

HaCaT

HeLa-bearing mice

Tian et al. (2015)

Nanosheets (15)

PcSi(OH)(mob) (20 wt%)

Encapsulated into PPIG4 dendrimer

Laser diode 690 nm, 0.3 W/cm2, 15 min (PDT/PTT, in vitro)

1O2

A2780/AD

A2780/AD-bearing mice

Taratula et al. (2013, 2015)

Nanocolloid Core@Shell NPs (15)

ZnPc (1.9 106 ZnPc/Au@GON NP)

ππ stacking

LED 660 nm, 0.2 W/cm2, 10 min (PDT); NIR laser 808 nm, 0.67 W/cm2, 20 min (PTT)

1O2

HeLa

Kim et al. (2015)

NPs nanoparticles, PS photosensitizer, ROS reactive oxygen species, nd not disclosed, ZnPc zinc phthalocyanine, UV ultraviolet, MB methylene blue, Ce6 chlorin e6, MitoTPP 5-(p-(4-bromo)butoxyphenyl)-10,15,20-triphenylporphyrin, HP hematoporphyrin, AdaTPP adamantanyl porphyrin, AP aptamer, CW continuous wave, TSCuPc tetrasulfonic acid tetrasodium salt copper phthalocyanine, DVDMS sinoporphyrin sodium, NIR near-infrared, ZnMAPc zinc monoamino phthalocyanine, ZnMCPPc zinc monocarboxyphenoxy phthalocyanine, ZnOCPc zinc octacarboxy phthalocyanine, POR meso-tetrakis(4-pyridyl)porphyrin tosylate salt, MYR meso-tetrakis(N-myristyl-4-pyridinium)porphyrin tosylate salt, AE chlorophyll derivatives in amaranth extract, SiNc4 silicon napthalocyanine bis (trihexylsilyloxide), HPPH 2-(1-hexyloxyethyl)-2-devinyl pyropheophorbide-alpha, SS disulfide, HA hyaluronic acid, Pep peptide, PcSi(OH)(mob) monosubstituted phthalocyanine derivative, PPIG4 polypropylenimine generation 4, GON graphene oxide nanocolloid

Conclusions

Nanoparticles (NPs) hold great promise for the design of new compounds for PDT. In this field, many biodegradable NPs have been formulated with the problem of controlling the NPs’ degradation and the release of the PS. Non-degradable NPs such as TiO2, ZnO, fullerene, and graphene are very promising NPs for PDT applications even if they are already well known in the field of photocatalysis. Their small size, low toxicity, and easy functionalization make them very good candidates for bioimaging and cancer therapy (PDT and/or PTT treatments). According to the results presented in this review and in the best of worlds, the ideal approach would allow us to develop theranostic platforms combining both bioimaging to localize tumor cells and a dual PDT/PTT treatment to eradicate tumor cells using a single wavelength while minimizing as much as possible the side effects. In order to achieve this ambitious goal, it will be necessary to modify the NP surface with (1) a contrast agent suitable for MRI, PET, or X-ray imaging, (2) PDT and PTT agents having photodynamic and photothermal activity in hypoxic and non-hypoxic conditions, and (3) a vector to target tumor cells.

Abbreviations

ABDA: 

9,10-anthracenediyl-bis(methylene)dimalonic acid

AcTMP: 

5-(4-acetamidophenyl)-10,15,20-tris(4-methoxyphenyl)porphyrin

AdaTPP: 

adamantanyl porphyrin

ADC: 

apparent diffusion coefficient

AE: 

amaranth extract

AFM: 

atomic force microscopy

5-ALA: 

5-aminolevulinic acid

AlPcS4

aluminum phthalocyanine chloride tetrasulfonate

AP: 

aptamer

APTES: 

3-aminopropyltriethoxysilane

ATMP: 

5-(4-amidophenyl)-10,15,20-tris(4-methoxyphenyl)porphyrin

ATP: 

adenosine-5′-triphosphate

βCD: 

beta-cyclodextrin

BDP: 

boron-dipyrromethene

BOLD: 

blood oxygenation level-dependent

BPEI: 

branched polyethylenimine

CaB: 

cathepsin B

CBC: 

complete blood cell count

CC50

cytotoxic concentration that induces 50% of cell death

Ce6: 

chlorin e6

CM-H2DCFDA: 

2,7-dichlorodihydrofluorescein diacetate acetyl ester

CW: 

continuous wave

DBMC-Cmbl: 

7,8-dihydroxy-4-bromomethylcoumarin-chlorambucil

DCFH-DA: 

2′,7′-dichlorodihydrofluorescein diacetate

DLS: 

dynamic light scattering

DMF: 

dimethylformamide

DNA: 

deoxyribonucleic acid

Dox: 

doxorubicin

DPBF: 

1,3-diphenylisobenzofuran

DSPE: 

1,2-distearoyl-sn-glycero-3-phosphoethanolamine

D-TMPyP: 

5-(4-formylphenyl)-10,15,20-tris(4-pyridyl)-porphyrin

DTT: 

dithiothreitol

DTX: 

docetaxel

DVDMS: 

sinoporphyrin sodium

DWI: 

diffusion-weighted imaging

EPR: 

enhanced permeability and retention

E-SWCNT: 

chirality-enriched (6,5) single-walled carbon nanotube

FA: 

folic acid

FDA: 

Food and Drug Administration

FCNV: 

fullerene C70 nanovesicle

FP: 

fine particle

FRET: 

fluorescence resonance energy transfer

FTEP: 

5-(4-formylphenyl)-10,15,20-tris[3-(N-ethylcarbozoyl)] porphyrin

FTIR: 

Fourier transform infrared

G: 

graphene

GO: 

graphene oxide

GON: 

graphene oxide nanocolloid

GR: 

graphene sheets

GSH: 

glutathione

HA: 

hyaluronic acid

HP: 

hematoporphyrin

HPPH: 

2-(1-hexyloxyethyl)-2-devinyl pyropheophorbide-alpha

H2TM4PyP (OTs)4

meso-tetrakis(4-pyridyl)porphyrin tosylate salt (POR)

H2TMy4PyP (OTs)4

meso-tetrakis(N-myristyl-4-pyridinium)porphyrin tosylate salt (MYR)

IC50

concentration that induces 50% of parasite inhibition

IR: 

infrared

LED: 

light-emitting diode

LHRH: 

luteinizing hormone-releasing hormone

LOGr: 

low-oxygen graphene

MA: 

malonic acid derivatives

MB: 

methylene blue

MFG: 

magnetic and fluorescent graphene

MitoTPP: 

5-(p-(4-trimethylammonium)-butoxyphenyl)-10,15,20-triphenylporphyrin bromide

mPEG: 

methoxy-poly(ethylene glycol)

MRI: 

magnetic resonance imaging

MTAP: 

meso-tetra(o-aminophenyl)porphyrin

MTCP: 

meso-tetra(4-carboxyphenyl)porphyrin

MTT: 

methylthiazolyl tetrazolium

NBT: 

nitroblue tetrazolium

NGO: 

nano-graphene oxide

NHS: 

N-hydroxysuccinimide

NIR: 

near-infrared

NP: 

nanoparticle

NR: 

nanorod

N-TiO2

nitrogen-doped TiO2

NV: 

nanovesicle

NW: 

nanowhisker

(OH)AlPcSmix: 

mixture of the di-, tri-, and tetra-sulfonated phthalocyanine derivatives

PBS: 

phosphate buffer saline

Pc: 

phthalocyanine

Pc(OH)(mob): 

monosubstituted silicon phthalocyanine

P–C60

porphyrin–[C60] fullerene dyads

P–C70

porphyrin–[C70] fullerene dyads

PEG: 

polyethylene glycol

pGO: 

polyethylene glycol-grafted graphene oxide

PLA: 

polylactide

PLL: 

polylysine

PS: 

photosensitizer

PDT: 

photodynamic therapy

Pep: 

peptide

PET: 

positron emission tomography

Φ Δ

singlet oxygen production quantum yield

PPDME: 

protoporphyrin dimethyl ester

PPIG4: 

polypropylenimine generation 4

PpIX: 

protoporphyrin IX

PTT: 

photothermal therapy

PVP: 

poly(vinylpyrrolidone)

Pyro: 

pyropheophorbide

rGO: 

reduced graphene oxide

ROS: 

reactive oxygen species

SEM: 

scanning electron microscopy

Sil: 

silane arm

SiNc4

silicon napthalocyanine bis(trihexylsilyloxide)

SLPDT: 

self-lighting photodynamic therapy

SOG: 

singlet oxygen generation

SOSG: 

singlet oxygen sensor green

SWNH: 

single-walled carbon nanohorn

SWCNT: 

single-walled carbon nanotube

TEM: 

transmission electron microscopy

TFC70

tri-malonate derivative of fullerene C70

TMPyP: 

trismethylpyridylporphyrin

TPP: 

tetraphenylporphyrin

TSCuPc: 

tetrasulfonic acid tetrasodium salt coper phthalocyanine

TSPP: 

meso-tetra(4-sulfonatophenyl)porphyrin

TTA-UC: 

triplet–triplet annihilation upconversion

UCNP: 

upconversion nanoparticles

UV: 

ultraviolet

VER: 

verteporfin

Vis: 

visible

WST-1: 

water-soluble tetrazolium salt

wt: 

weight

ZnMAPc: 

zinc monoamino phthalocyanine

ZnMCPPc: 

zinc monocarboxyphenoxy phthalocyanine

ZnOPc: 

zinc octacarboxy phthalocyanine

ZnPc: 

zinc phthalocyanine

ZnTMAAPc: 

2,(3),9(10),16(17),23(24)-tetrakis-(mercaptoacetic acid phthalocyaninato) zinc(II)

ZnTMPAPc: 

2,(3),9(10),16(17),23(24)-tetrakis-(mercaptopropanoic acid phthalocyaninato) zinc(II)

Declarations

Authors’ contributions

The manuscript was written through contributions from all the authors. All authors read and approved the final manuscript.

Acknowledgements

No additional acknowledgements.

Competing interests

The authors declare that they have no competing interests.

Availability of data and materials

Not applicable.

Consent for publication

Not applicable.

Ethics approval and consent to participate

Studies involving human participants, human data, or human tissue: not applicable. Studies involving animals: All studies reported in this review have received ethical approval (see original articles).

Funding

Not applicable.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Authors’ Affiliations

(1)
Laboratoire Réactions et Génie des Procédés, Université de Lorraine-CNRS, UMR 7274
(2)
Laboratoire de Chimie Physique Macromoléculaire, Université de Lorraine-CNRS, UMR 7375
(3)
School of Pharmaceutical Sciences, Universiti Sains Malaysia
(4)
Laboratory of Materials, Catalysis, Environment and Analytical Methods, Faculty of Sciences I, Lebanese University

References

  1. Ahn J-H, Hong BH. Things you could do with graphene. Nat Nanotechnol. 2014;9:737–47.View ArticleGoogle Scholar
  2. Alvarez MG, Prucca C, Milanesio ME, Durantini EN, Rivarola V. Photodynamic activity of a new sensitizer derived from porphyrin-C-60 dyad and its biological consequences in a human carcinoma cell line. Int J Biochem Cell Biol. 2006;38:2092–101.View ArticleGoogle Scholar
  3. Alvarez MG, Milanesio M, Rivarola V, Durantini E, Batlle A, Fukuda H. Endogenous and exogenous porphyrins as photosensitizers in the Hep-2 human carcinoma cell line. Cell Mol Biol. 2009;55:8–14.Google Scholar
  4. Atif M, Fakhar-e-Alam M, Al Salhi MS. Role of sensitivity of zinc oxide nanorods (ZnO-NRs) based photosensitizers in hepatocellular site of biological tissue. Laser Phys. 2011;21:1950–61.View ArticleGoogle Scholar
  5. Ballatore MB, Spesia MB, Milanesio ME, Durantini EN. Synthesis, spectroscopic properties and photodynamic activity of porphyrin-fullerene C-60 dyads with application in the photodynamic inactivation of Staphylococcus aureus. Eur J Med Chem. 2014;83:685–94.View ArticleGoogle Scholar
  6. Belik P, Gugel A, Kraus A, Spickermann J, Enkelmann V, Frank G, Mullen K. The Diels–Alder adduct of C-60 and 4,5-dimethoxy-o-quinodimethane synthesis, crystal-structure, and donor-acceptor behavior. Adv Mater. 1993;5:854–6.View ArticleGoogle Scholar
  7. Benachour H, Seve A, Bastogne T, Frochot C, Vanderesse R, Jasniewski J, Miladi I, Billotey C, Tillement O, Lux F, Barberi-Heyob M. Multifunctional peptide-conjugated hybrid silica nanoparticles for photodynamic therapy and MRI. Theranostics. 2012;2:889–904.View ArticleGoogle Scholar
  8. Berg K, Nordstrand S, Selbo PK, Diem TTT, Angell-Petersen E, Hogset A. Disulfonated tetraphenyl chlorin (TPCS2a), a novel photosensitizer developed for clinical utilization of photochemical internalization. Photochem Photobiol Sci. 2011;10:1637–51.View ArticleGoogle Scholar
  9. Bingel C. Cyclopropylation of fullerenes. Chem Ber Rec. 1993;126:1957–9.View ArticleGoogle Scholar
  10. Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol. 2015;33:941–51.View ArticleGoogle Scholar
  11. Bogdan N, Vetrone F, Ozin GA, Capobianco JA. Synthesis of ligand-free colloidally stable water dispersible brightly luminescent lanthanide-doped upconverting nanoparticles. Nano Lett. 2011;11:835–40.View ArticleGoogle Scholar
  12. Bulin AL, Truillet C, Chouikrat R, Lux F, Frochot C, Amans D, Ledoux G, Tillement O, Perriat P, Barberi-Heyob M, Dujardin C. X-ray induced singlet oxygen activation with nanoscintillator coupled porphyrins. J Phys Chem C. 2013;117:21583–9.View ArticleGoogle Scholar
  13. Burlaka AP, Sidorik YP, Prylutska SV, Matyshevska OP, Golub OA, Prylutskyy YI, Scharff P. Catalytic system of the reactive oxygen species on the C60 fullerene basis. Exp Oncol. 2004;26:326–7.Google Scholar
  14. Calixto GMF, Bernegossi J, de Freitas LM, Fontana CR, Chorilli M. Nanotechnology-based drug delivery systems for photodynamic therapy of cancer: a review. Molecules. 2016;21:342.View ArticleGoogle Scholar
  15. Cao JB, An HQ, Huang XL, Fu GF, Zhuang RQ, Zhu L, Xie J, Zhang F. Monitoring of the tumor response to nano-graphene oxide-mediated photothermal/photodynamic therapy by diffusion-weighted and BOLD MRI. Nanoscale. 2016;8:10152–9.View ArticleGoogle Scholar
  16. Chang H-I, Yeh M-K. Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy. Int J Nanomed. 2012;7:49–60.Google Scholar
  17. Chang GR, Wang YL, Gong BY, Xiao YZ, Chen Y, Wang SH, Li SK, Huang FZ, Shen YH, Xie AJ. Reduced graphene oxide/amaranth extract/AuNPs composite hydrogel on tumor cells as integrated platform for localized and multiple synergistic therapy. ACS Appl Mater Interfaces. 2015;7:11246–56.View ArticleGoogle Scholar
  18. Chen W, Zhang J. Using nanoparticles to enable simultaneous radiation and photodynamic therapies for cancer treatment. J Nanosci Nanotechnol. 2006;6:1159–66.View ArticleGoogle Scholar
  19. Cho Y, Choi Y. Graphene oxide-photosensitizer conjugate as a redox-responsive theranostic agent. Chem Commun. 2012;48:9912–4.View ArticleGoogle Scholar
  20. Cho WS, Duffin R, Thielbeer F, Bradley M, Megson IL, Macnee W, Poland CA, Tran CL, Donaldson K. Zeta potential and solubility to toxic ions as mechanisms of lung inflammation caused by metal/metal oxide nanoparticles. Toxicol Sci. 2012;126:469–77.View ArticleGoogle Scholar
  21. Cho Y, Kim H, Choi Y. A graphene oxide-photosensitizer complex as an enzyme-activatable theranostic agent. Chem Commun. 2013;49:1202–4.View ArticleGoogle Scholar
  22. Cho HY, Ansems RBM, Scott LT. Site-selective covalent functionalization at interior carbon atoms and on the rim of circumtrindene, a C36H12 open geodesic polyarene. Beilstein J Org Chem. 2014;10:956–68.View ArticleGoogle Scholar
  23. Chouikrat R, Seve A, Vanderesse R, Benachour H, Barberi-Heyob M, Richeter S, Raehm L, Durand JO, Verelst M, Frochot C. Non polymeric nanoparticles for photodynamic therapy applications: recent developments. Curr Med Chem. 2012;19:781–92.View ArticleGoogle Scholar
  24. Chu X, Li K, Guo H, Zheng H, Shuda S, Wand X, Zhang J, Chen W, Zhang Y. Exploration of graphitic-C3N4 quantum dots for microwave-induced photodynamic therapy. ACS Biomater Sci Eng. 2017;3:1836–44.View ArticleGoogle Scholar
  25. Colombeau L, Acherar S, Baros F, Arnoux P, Gazzali AM, Zaghdoudi K, Toussaint M, Vanderesse R, Frochot C. Inorganic nanoparticles for photodynamic therapy. Top Curr Chem. 2016;370:113–34.View ArticleGoogle Scholar
  26. Constantin C, Neagu M, Ion R-M, Gherghiceanu M, Stavaru C. Fullerene–porphyrin nanostructures in photodynamic therapy. Nanomedicine. 2010;5:307–17.View ArticleGoogle Scholar
  27. Couleaud P, Bechet D, Vanderesse R, Barberi-Heyob M, Faure AC, Roux S, Tillement O, Porhel S, Guillemin F, Frochot C. Functionalized silica-based nanoparticles for photodynamic therapy. Nanomedicine. 2011;6:995–1009.View ArticleGoogle Scholar
  28. Crane JD, Hitchcock PB, Kroto HW, Taylor R, Walton DRM. Preparation and characterization of C-60 (ferrocene)2. J Chem Soc Chem Commun. 1992;24:1764–5.View ArticleGoogle Scholar
  29. De Jong WH, Borm PJA. Drug delivery and nanoparticles: applications and hazards. Int J Nanomed. 2008;3:133–49.View ArticleGoogle Scholar
  30. Dong HQ, Zhao ZL, Wen HY, Li YY, Guo FF, Shen AJ, Frank P, Lin C, Shi DL. Poly(ethylene glycol) conjugated nano-graphene oxide for photodynamic therapy. Sci China Chem. 2010;53:2265–71.View ArticleGoogle Scholar
  31. Dong HQ, Dong CY, Ren TB, Li YY, Shi DL. Surface-engineered graphene-based nanomaterials for drug delivery. J Biomed Nanotechnol. 2014;10:2086–106.View ArticleGoogle Scholar
  32. D’Souza S, Moeno S, Nyokong T. Effects of ZnO nanohexagons and nanorods on the fluorescence behavior of metallophthalocyanines. Polyhedron. 2015;85:476–81.View ArticleGoogle Scholar
  33. Fakhar-e-Alam M, Firdous S, Atif M, Khan Y, Zaidi SSZ, Suleman R, Rehman A, Khan RU, Nawaz M, Ikram M. The potential applications of ZnO nanoparticles conjugated with ALA and photofrin as a biomarker in HepG2 cells. Laser Phys. 2011a;21:2156–64.View ArticleGoogle Scholar
  34. Fakhar-e-Alam M, Kishwar S, Khan Y, Siddique M, Atif M, Nur O, Willander M. Tumoricidal effects of nanomaterials in HeLa cell line. Laser Phys. 2011b;21:1978–88.View ArticleGoogle Scholar
  35. Fakhar-e-Alam M, Ali SMU, Ibupoto ZH, Kimleang K, Atif M, Kashif M, Loong FK, Hashim U, Willander M. Sensitivity of A-549 human lung cancer cells to nanoporous zinc oxide conjugated with photofrin. Lasers Med Sci. 2012;27:607–14.View ArticleGoogle Scholar
  36. Fakhar-e-Alam M, Kishwar S, Willander M. Photodynamic effects of zinc oxide nanowires in skin cancer and fibroblast. Lasers Med Sci. 2014a;29:1189–94.View ArticleGoogle Scholar
  37. Fakhar-e-Alam M, Rahim S, Atif M, Aziz MH, Malick MI, Zaidi SSZ, Suleman R, Majid A. ZnO nanoparticles as drug delivery agent for photodynamic therapy. Laser Phys Lett. 2014b;11:025601.View ArticleGoogle Scholar
  38. Fungo F, Otero LA, Sereno L, Silber JJ, Durantini EN. Synthesis of porphyrin dyads with potential use in solar energy conversion. J Mater Chem. 2000;10:645–50.View ArticleGoogle Scholar
  39. Fungo F, Otero LA, Sereno L, Silber JJ, Durantini EN. Synthesis of a porphyrin-C-60 dyad for potential use in solar energy conversion. Dyes Pigments. 2001;50:163–70.View ArticleGoogle Scholar
  40. Gangopadhyay M, Mukhopadhyay SK, Karthik S, Barman S, Singh NDP. Targeted photoresponsive TiO2-coumarin nanoconjugate for efficient combination therapy in MDA-MB-231 breast cancer cells: synergic effect of photodynamic therapy (PDT) and anticancer drug chlorambucil. MedChemComm. 2015;6:769–77.View ArticleGoogle Scholar
  41. Gollavelli G, Ling YC. Magnetic and fluorescent graphene for dual modal imaging and single light induced photothermal and photodynamic therapy of cancer cells. Biomaterials. 2014;35:4499–507.View ArticleGoogle Scholar
  42. Goncalves G, Vila M, Portoles MT, Vallet-Regi M, Gracio J, Marques P. Nano-graphene oxide: a potential multifunctional platform for cancer therapy. Adv Healthc Mater. 2013;2:1072–90.View ArticleGoogle Scholar
  43. Gu Y. Microwave induced photodynamic therapy. 2013. WO2013006176-A1.Google Scholar
  44. Guan M, Dong H, Ge J, Chen D, Sun L, Li S, Wang C, Yan C, Wang P, Shu C. Multifunctional upconversion-nanoparticles-trismethylpyridylporphyrin-fullerene nanocomposite: a near-infrared light-triggered theranostic platform for imaging-guided photodynamic therapy. NPG Asia Mater. 2015a;7:e205.View ArticleGoogle Scholar
  45. Guan M, Qin T, Ge J, Zhen M, Xu W, Chen D, Li S, Wang C, Su H, Shu C. Amphiphilic trismethylpyridylporphyrin-fullerene (C-70) dyad: an efficient photosensitizer under hypoxia conditions. J Mater Chem B. 2015b;3:776–83.View ArticleGoogle Scholar
  46. Guan MR, Ge JC, Wu JY, Zhang GQ, Chen DQ, Zhang W, Zhang Y, Zou TJ, Zhen MM, Wang CR, Chu TW, Hao XJ, Shu CY. Fullerene/photosensitizer nanovesicles as highly efficient and clearable phototheranostics with enhanced tumor accumulation for cancer therapy. Biomaterials. 2016;103:75–85.View ArticleGoogle Scholar
  47. Guo X, Ding R, Zhang Y, Ye L, Liu X, Chen C, Zhang Z, Zhang Y. Dual role of photosensitizer and carrier material of fullerene in micelles for chemo-photodynamic therapy of cancer. J Pharm Sci. 2014;103:3225–34.View ArticleGoogle Scholar
  48. Hirsch A. Addition-reactions of buckminsterfullerene (C-60). Synthesis. 1995;1995:895–913.View ArticleGoogle Scholar
  49. Høgset A, Prasmickaite L, Selbo PK, Hellum M, Engesaeter BB, Bonsted A, Berg K. Photochemical internalisation in drug and gene delivery. Adv Drug Deliv Rev. 2004;56:95–115.View ArticleGoogle Scholar
  50. Hu Z, Li J, Li CY, Zhao SJ, Li N, Wang YF, Wei F, Chen L, Huang YD. Folic acid-conjugated graphene-ZnO nanohybrid for targeting photodynamic therapy under visible light irradiation. J Mater Chem B. 2013;1:5003–13.View ArticleGoogle Scholar
  51. Huang P, Xu C, Lin J, Wang C, Wang XS, Zhang CL, Zhou XJ, Guo SW, Cui DX. Folic acid-conjugated graphene oxide loaded with photosensitizers for targeting photodynamic therapy. Theranostics. 2011;1:240–50.View ArticleGoogle Scholar
  52. Huang Y-Y, Sharma SK, Dai T, Chung H, Yaroslavsky A, Garcia-Diaz M, Chang J, Chiang LY, Hamblin MR. Can nanotechnology potentiate photodynamic therapy? Nano Rev. 2012;1:111–46.Google Scholar
  53. Huang Y-Y, Sharma SK, Yin R, Agrawal T, Chiang LY, Hamblin MR. Functionalized fullerenes in photodynamic therapy. J Biomed Nanotechnol. 2014;10:1918–36.View ArticleGoogle Scholar
  54. Huang P, Wang SJ, Wang XS, Shen GX, Lin J, Wang Z, Guo SW, Cui DX, Yang M, Chen XY. Surface functionalization of chemically reduced graphene oxide for targeted photodynamic therapy. J Biomed Nanotechnol. 2015;11:117–25.View ArticleGoogle Scholar
  55. Ion RM. Porphyrinic nano-sensitizers encapsulated into colloidal carriers. Rom J Phys. 2004;49:867–71.Google Scholar
  56. Ion R-M, Brezoi D-V. New nano-sized sensing drug and its clinical application. Solid State Phenom. 2005a;1006:79–82.View ArticleGoogle Scholar
  57. Ion R-M, Brezoi D-V. New nano-sized sensing drug and its clinical application. SSP. 2005b;1006:79–82.View ArticleGoogle Scholar
  58. Ion RM, Fierascu RC, Neagu M, Constantin C, Stavaru C. Porphyrin (TPP)-polyvinylpyrrolidone (PVP)-fullerene (C-60) triad as novel sensitizer in photodynamic therapy. Sci Adv Mater. 2010;2:223–9.View ArticleGoogle Scholar
  59. Ion RM, Daicoviciu D, Filip AG, Clichici S, Muresan A. Oxidative stress effects of fullerene–porphyrin derivatives in photodynamic therapy. J Porphyr Phthalocyanines. 2012;16:870–7.View ArticleGoogle Scholar
  60. Jia X, Jia L. Nanoparticles improve biological functions of phthalocyanine photosensitizers used for photodynamic therapy. Curr Drug Metab. 2012;13:1119–22.View ArticleGoogle Scholar
  61. Jiang BP, Hu LF, Shen XC, Ji SC, Shi ZJ, Liu CJ, Zhang L, Liang H. One-step preparation of a water-soluble carbon nanohorn/phthalocyanine hybrid for dual-modality photothermal and photodynamic therapy. ACS Appl Mater Interfaces. 2014a;6:18008–17.View ArticleGoogle Scholar
  62. Jiang BP, Hu LF, Wang DJ, Ji SC, Shen XC, Liang H. Graphene loading water-soluble phthalocyanine for dual-modality photothermal/photodynamic therapy via a one-step method. J Mater Chem B. 2014b;2:7141–8.View ArticleGoogle Scholar
  63. Kim YK, Na HK, Kim S, Jang H, Chang SJ, Min DH. One-pot synthesis of multifunctional Au@graphene oxide nanocolloid core@shell nanoparticles for Raman bioimaging, photothermal, and photodynamic therapy. Small. 2015;11:2527–35.View ArticleGoogle Scholar
  64. Kotelnikov AI, Rybkin AY, Khakina EA, Kornev AB, Barinov AV, Goryachev NS, Ivanchikhina AV, Peregudov AS, Martynenkoa VM, Troshin PA. Hybrid photoactive fullerene derivative-ruboxyl nanostructures for photodynamic therapy. Org Biomol Chem. 2013;11:4397–404.View ArticleGoogle Scholar
  65. Krishna KV, Menard-Moyon C, Verma S, Bianco A. Graphene-based nanomaterials for nanobiotechnology and biomedical applications. Nanomedicine. 2013;8:1669–88.View ArticleGoogle Scholar
  66. Kroto HW, Heath JR, Obrien SC, Curl RF, Smalley RE. C-60—Buckminsterfullerene. Nature. 1985;318:162–3.View ArticleGoogle Scholar
  67. Laptev VP, Petrov VV, Andreev SM, Panferova NG, Romanova VS, Ovchinnikov AE. Composition for photodynamic therapy of malignant tumors comprises a fullerene amino acid or dipeptide derivative. WO2007075119-A1; RU2323722-C2; US2009012008-A1. 2009.Google Scholar
  68. Lee KP, Trochimowicz HJ, Reinhardt CF. Pulmonary response of rats exposed to titanium dioxide (TiO2) by inhalation for two years. Toxicol Appl Pharmacol. 1985;79:179–92.View ArticleGoogle Scholar
  69. Lee JC, Kim TY, Kang SH, Shim YK. Synthesis of covalently linked chlorin–fullerene dyads. Bull Korean Chem Soc. 2001;22:257–8.Google Scholar
  70. Li F, Park S-J, Ling D, Park W, Han JY, Na K, Char K. Hyaluronic acid-conjugated graphene oxide/photosensitizer nanohybrids for cancer targeted photodynamic therapy. J Mater Chem B. 2013;1:1678–86.View ArticleGoogle Scholar
  71. Li Z, Pan L-L, Zhang F-L, Zhu X-L, Liu Y, Zhang Z-Z. 5-Aminolevulinic acid-loaded fullerene nanoparticles for in vitro and in vivo photodynamic therapy. Photochem Photobiol. 2014;90:1144–9.Google Scholar
  72. Li Y, Dong HQ, Li YY, Shi DL. Graphene-based nanovehicles for photodynamic medical therapy. Int J Nanomed. 2015a;10:2451–9.View ArticleGoogle Scholar
  73. Li Z, Zhang FL, Pan LL, Zhu XL, Zhang ZZ. Preparation and characterization of injectable mitoxantrone poly(lactic acid)/fullerene implants for in vivo chemo-photodynamic therapy. J Photochem Photobiol B Biol. 2015b;149:51–7.View ArticleGoogle Scholar
  74. Liu Y, Zhang Y, Wang S, Pope C, Chen W. Optical behaviors of ZnO-porphyrin conjugates and their potential applications for cancer treatment. Appl Phys Lett. 2008;92:143901.View ArticleGoogle Scholar
  75. Liu G, Qin HM, Amano T, Murakami T, Komatsu N. Direct fabrication of the graphene-based composite for cancer phototherapy through graphite exfoliation with a photosensitizer. ACS Appl Mater Interfaces. 2015a;7:23402–6.View ArticleGoogle Scholar
  76. Liu XM, Que I, Kong XG, Zhang YL, Tu LP, Chang YL, Wang TT, Chan A, Lowik C, Zhang H. In vivo 808 nm image-guided photodynamic therapy based on an upconversion theranostic nanoplatform. Nanoscale. 2015b;7:14914–23.View ArticleGoogle Scholar
  77. Lohani A, Verma A, Joshi H, Yadav N, Karki N. Nanotechnology-based cosmeceuticals. ISRN Dermatol. 2014;2014:843687. doi:10.1155/2014/843687.
  78. Lopez T, Ortiz E, Alvarez M, Navarrete J, Odriozola JA, Martinez-Ortega F, Paez-Mozo EA, Escobar P, Espinoza KA, Rivero IA. Study of the stabilization of zinc phthalocyanine in sol–gel TiO2 for photodynamic therapy applications. Nanomed Nanotechnol Biol Med. 2010;6:777–85.View ArticleGoogle Scholar
  79. Lu KQ, He QY, Chen L, Ai BQ, Xiong JW. The comparative PDT experiment of the inactivation of HL60 on modified TiO2 nanoparticles. J Nanomater. 2015;2015:540247. doi:10.1155/2015/540247.
  80. Lucky SS, Soo KC, Zhang Y. Nanoparticles in photodynamic therapy. Chem Rev. 2015;115:1990–2042.View ArticleGoogle Scholar
  81. Luo MD, Shen CC, Feltis BN, Martin LL, Hughes AE, Wright PFA, Turney TW. Reducing ZnO nanoparticle cytotoxicity by surface modification. Nanoscale. 2014;6:5791–8.View ArticleGoogle Scholar
  82. Maggini M, Scorrano G, Prato M. Addition of azomethine ylides to C-60—synthesis, characterization, and functionalization of fullerene pyrrolidines. J Am Chem Soc. 1993;115:9798–9.View ArticleGoogle Scholar
  83. Martin N, Sanchez L, Illescas B, Perez I. C-60-based electroactive organofullerenes. Chem Rev. 1998;98:2527–47.View ArticleGoogle Scholar
  84. Meier MS, Poplawska M. The addition of nitrile oxides to C60. Tetrahedron. 1996;52:5043–52.View ArticleGoogle Scholar
  85. Mermut O, Diamond KR, Cormier JF, Gallant P, Ho N, Leclair S, Marois JS, Noiseux I, Morin JF, Patterson MS, Vernon ML. The use of magnetic field effects on photosensitizer luminescence as a novel probe for optical monitoring of oxygen in photodynamic therapy. Phys Med Biol. 2009;54:1–16.View ArticleGoogle Scholar
  86. Miao W, Shim G, Lee S, Lee S, Choe YS, Oh YK. Safety and tumor tissue accumulation of pegylated graphene oxide nanosheets for co-delivery of anticancer drug and photosensitizer. Biomaterials. 2013;34:3402–10.View ArticleGoogle Scholar
  87. Milanesio ME, Gervaldo M, Otero LA, Sereno L, Silber JJ, Durantini EN. Synthesis and photophysical properties of Zn(II) porphyrin-C-60 dyad with potential use in solar cells. J Phys Org Chem. 2002;15:844–51.View ArticleGoogle Scholar
  88. Milanesio ME, Alvarez MG, Rivarola V, Silber JJ, Durantini EN. Porphyrin-fullerene C-60 dyads with high ability to form photoinduced charge-separated state as novel sensitizers for photodynamic therapy. Photochem Photobiol. 2005;81:891–7.View ArticleGoogle Scholar
  89. Monge-Fuentes V, Muehlmann LA, de Azevedo RB. Perspectives on the application of nanotechnology in photodynamic therapy for the treatment of melanoma. Nano Rev. 2014;5. doi:10.3402/nano.v5.24381.
  90. Novoselov KS, Geim AK, Morozov SV, Jiang D, Zhang Y, Dubonos SV, Grigorieva IV, Firsov AA. Electric field effect in atomically thin carbon films. Science. 2004;306:666–9.View ArticleGoogle Scholar
  91. Ogbodu RO, Nyokong T. Effect of bovine serum albumin and single walled carbon nanotube on the photophysical properties of zinc octacarboxy phthalocyanine. Spectrochim Acta Part A Mol Biomol Spectrosc. 2014;121:81–7.View ArticleGoogle Scholar
  92. Ogbodu RO, Antunes E, Nyokong T. Physicochemical properties of zinc monoamino phthalocyanine conjugated to folic acid and single walled carbon nanotubes. Polyhedron. 2013a;60:59–67.View ArticleGoogle Scholar
  93. Ogbodu RO, Antunes E, Nyokong T. Physicochemical properties of a zinc phthalocyanine-pyrene conjugate adsorbed onto single walled carbon nanotubes. Dalton Trans. 2013b;42:10769–77.View ArticleGoogle Scholar
  94. Ogbodu RO, Limson JL, Prinsloo E, Nyokong T. Photophysical properties and photodynamic therapy effect of zinc phthalocyanine-spermine-single walled carbon nanotube conjugate on MCF-7 breast cancer cell line. Synth Met. 2015a;204:122–32.View ArticleGoogle Scholar
  95. Ogbodu RO, Ndhundhuma I, Karsten A, Nyokong T. Photodynamic therapy effect of zinc monoamino phthalocyanine-folic acid conjugate adsorbed on single walled carbon nanotubes on melanoma cells. Spectrochim Acta Part A Mol Biomol Spectrosc. 2015b;137:1120–5.View ArticleGoogle Scholar
  96. Ojha K, Anjaneyulu O, Ganguil AK. Graphene-based hybrid materials: synthetic approaches and properties. Curr Sci. 2014;107:397–418.Google Scholar
  97. Olivo M, Bhuvaneswari R, Lucky SS, Dendukuri N, Thong PSP. Targeted therapy of cancer using photodynamic therapy in combination with multi-faceted anti-tumor modalities. Pharmaceuticals. 2010;3:1507–29.View ArticleGoogle Scholar
  98. Orecchioni M, Cabizza R, Bianco A, Delogu LG. Graphene as cancer theranostic tool: progress and future challenges. Theranostics. 2015;5:710–23.View ArticleGoogle Scholar
  99. Osmond-McLeod MJ, Oytam Y, Osmond RIW, Sobhanmanesh F, McCall MJ. Surface coating protect against the in vitro toxicity of zinc oxide nanoparticles in human hepatic stellate cells. J Nanomed Nanotechnol. 2014;5:232.View ArticleGoogle Scholar
  100. Pan XB, Xie J, Li Z, Chen MX, Wang MY, Wang PN, Chen L, Mi L. Enhancement of the photokilling effect of aluminum phthalocyanine in photodynamic therapy by conjugating with nitrogen-doped TiO2 nanoparticles. Colloids Surf B Biointerfaces. 2015;130:292–8.View ArticleGoogle Scholar
  101. Pandurangan M, Kim DH. In vitro toxicity of zinc oxide nanoparticles: a review. J Nanopart Res. 2015;17:158.View ArticleGoogle Scholar
  102. Raccichini R, Varzi A, Passerini S, Scrosati B. The role of graphene for electrochemical energy storage. Nat Mater. 2015;14:271–9.View ArticleGoogle Scholar
  103. Rahman M, Akhter S, Ahmad MZ, Ahmad J, Addo RT, Ahmad FJ, Pichon C. Emerging advances in cancer nanotheranostics with graphene nanocomposites: opportunities and challenges. Nanomedicine. 2015;10:2405–22.View ArticleGoogle Scholar
  104. Rancan F, Helmreich M, Molich A, Jux N, Hirsch A, Roder B, Witt C, Bohm F. Fullerene-pyropheophorbide a complexes as sensitizer for photodynamic therapy: uptake and photo-induced cytotoxicity on Jurkat cells. J Photochem Photobiol B Biol. 2005;80:1–7.View ArticleGoogle Scholar
  105. Rancan F, Helmreich M, Moelich A, Ermilov EA, Jux N, Roeder B, Hirsch A, Boehm F. Synthesis and in vitro testing of a pyropheophorbide-a-fullerene hexakis adduct immunoconjugate for photodynamic therapy. Bioconj Chem. 2007a;18:1078–86.View ArticleGoogle Scholar
  106. Rancan F, Helmreich M, Moelich A, Jux N, Hirsch A, Roeder B, Boehm F. Intracellular uptake and phototoxicity of 3(1),3(2)-didehydrophytochlorin-fullerene hexaadducts. Photochem Photobiol. 2007b;83:1330–8.View ArticleGoogle Scholar
  107. Reddy JA, Allagadda VM, Leamon CP. Targeting therapeutic and imaging agents to folate receptor positive tumors. Curr Pharm Biotechnol. 2005;6:131–50.View ArticleGoogle Scholar
  108. Rehman FU, Zhao CQ, Wu CY, Jiang H, Selke M, Wang XM. Influence of photoactivated tetra sulphonatophenyl porphyrin and TiO2 nanowhiskers on rheumatoid arthritis infected bone marrow stem cell proliferation in vitro and oxidative stress biomarkers in vivo. RSC Adv. 2015;5:107285–92.View ArticleGoogle Scholar
  109. Rehman FU, Zhao CQ, Jiang H, Selke M, Wang XM. Photoactivated TiO2 nanowhiskers and tetra sulphonatophenyl porphyrin normoglycemic effect on diabetes mellitus during photodynamic therapy. J Nanosci Nanotechnol. 2016a;16:12691–4.View ArticleGoogle Scholar
  110. Rehman FU, Zhao CQ, Jiang H, Selke M, Wang XM. Protective effect of TiO2 nanowhiskers on tetra sulphonatophenyl porphyrin (TSPP) complexes induced oxidative stress during photodynamic therapy. Photodiagn Photodyn Ther. 2016b;13:267–75.View ArticleGoogle Scholar
  111. Roblero-Bartolon GV, Ramon-Gallegos E. Use of nanoparticles (NP) in photodynamic therapy (PDT) against cancer. Gac Med Mex. 2015;151:85–98.Google Scholar
  112. Rong PF, Yang K, Srivastan A, Kiesewetter DO, Yue XY, Wang F, Nie LM, Bhirde A, Wang Z, Liu Z, Niu G, Wang W, Chen XY. Photosensitizer loaded nano-graphene for multimodality imaging guided tumor photodynamic therapy. Theranostics. 2014;4:229–39.View ArticleGoogle Scholar
  113. Sadjadpour S, Safarian S, Zargar SJ, Sheibani NR. Antiproliferative effects of ZnO, ZnO-MTCP, and ZnO-CuMTCP nanoparticles with safe intensity UV and X-ray irradiation. Biotechnol Appl Biochem. 2016;63:113–24.View ArticleGoogle Scholar
  114. Safar GAM, Gontijo RN, Fantini C, Martins DCS, Idemori YM, Pinheiro MVB, Krambrock K. Enhanced oxygen singlet production by hybrid system of porphyrin and enriched (6,5) single-walled carbon nanotubes for photodynamic therapy. J Phys Chem C. 2015;119:4344–50.View ArticleGoogle Scholar
  115. Sahu A, Choi WI, Lee JH, Tae G. Graphene oxide mediated delivery of methylene blue for combined photodynamic and photothermal therapy. Biomaterials. 2013;34:6239–48.View ArticleGoogle Scholar
  116. Sega EI, Low PS. Tumor detection using folate receptor-targeted imaging agents. Cancer Metastasis Rev. 2008;27:655–64.View ArticleGoogle Scholar
  117. Senthilkumar S, Hariharan R, Suganthi A, Ashokkumar M, Rajarajan M, Pitchumani K. Synergistic photodynamic action of ZnO nanomaterials encapsulated meso-tetra(4-sulfonatophenyl) porphyrin. Powder Technol. 2013;237:497–505.View ArticleGoogle Scholar
  118. Sharma SK, Chiang LY, Hamblin MR. Photodynamic therapy with fullerenes in vivo: reality or a dream? Nanomedicine. 2011;6:1813–25.View ArticleGoogle Scholar
  119. Shen H, Zhang LM, Liu M, Zhang ZJ. Biomedical applications of graphene. Theranostics. 2012;2:283–94.View ArticleGoogle Scholar
  120. Shen Y, Shuhendler AJ, Ye D, Xu J-J, Chen H-Y. Two-photon excitation nanoparticles for photodynamic therapy. Chem Soc Rev. 2016;45:6725–41.View ArticleGoogle Scholar
  121. Shi H, Magaye R, Castranova V, Zhao J. Titanium dioxide nanoparticles: a review of current toxicological data. Part Fibre Toxicol. 2013;10:15.View ArticleGoogle Scholar
  122. Shi JJ, Wang L, Gao J, Liu Y, Zhang J, Ma R, Liu RY, Zhang ZZ. A fullerene-based multi-functional nanoplatform for cancer theranostic applications. Biomaterials. 2014;35:5771–84.View ArticleGoogle Scholar
  123. Shi JJ, Chen ZY, Wang L, Wang BH, Xu LH, Hou L, Zhang ZZ. A tumor-specific cleavable nanosystem of PEG-modified C60@Au hybrid aggregates for radio frequency-controlled release, hyperthermia, photodynamic therapy and X-ray imaging. Acta Biomater. 2016;29:282–97.View ArticleGoogle Scholar
  124. Stallivieri A, Baros F, Arnoux P, Vanderesse R, Barberi-Heyob M, Frochot C. Production of singlet oxygen by nanoparticle-bound photosensitizers. In: Nonell, Flors, editors. Singlet oxygen: applications in biosciences and nanosciences, vol. 1. London: The Royal Society of Chemistry; 2016. p. 209–23.Google Scholar
  125. Stinchcombe J, Penicaud A, Bhyrappa P, Boyd PDW, Reed CA. Buckminsterfulleride(1-) salts—synthesis, EPR, and the Jahn-Teller distortion of C-60. J Am Chem Soc. 1993;115:5212–7.View ArticleGoogle Scholar
  126. Taratula O, Schumann C, Naleway MA, Pang AJ, Chon KJ, Taratula O. A multifunctional theranostic platform based on phthalocyanine-loaded dendrimer for image-guided drug delivery and photodynamic therapy. Mol Pharm. 2013;10:3946–58.View ArticleGoogle Scholar
  127. Taratula O, Patel M, Schumann C, Naleway MA, Pang AJ, He HX, Taratula O. Phthalocyanine-loaded graphene nanoplatform for imaging-guided combinatorial phototherapy. Int J Nanomed. 2015;10:2347–62.View ArticleGoogle Scholar
  128. Tian B, Wang C, Zhang S, Feng L, Liu Z. Photothermally enhanced photodynamic therapy delivered by nano-graphene oxide. ACS Nano. 2011;5:7000–9.View ArticleGoogle Scholar
  129. Tian JW, Ding L, Wang QB, Hu YP, Jia L, Yu JS, Ju HX. Folate receptor-targeted and cathepsin B-activatable nanoprobe for in situ therapeutic monitoring of photosensitive cell death. Anal Chem. 2015;87:3841–8.View ArticleGoogle Scholar
  130. Tokuyama H, Yamago S, Nakamura E. Photoinduced biochemical activity of fullerene carboxylic acid. J Am Chem Soc. 1993;115:7918–9.View ArticleGoogle Scholar
  131. Vanderesse R, Frochot C, Barberi-Heyob M, Richeter S, Raehm L, Durand JO. Nanoparticles for photodynamic therapy applications, In: Prokop, editor. Intracellular delivery: fundamentals and applications. Dordrecht: Springer; 2011; p. 511–65.Google Scholar
  132. Verhille M, Couleaud P, Vanderesse R, Brault D, Barberi-Heyob M, Frochot C. Modulation of photosensitization processes for an improved targeted photodynamic therapy. Curr Med Chem. 2010;17:3925–43.View ArticleGoogle Scholar
  133. Voon SH, Kiew LV, Lee HB, Lim SH, Noordin MI, Kamkaew A, Burgess K, Chung LY. In vivo studies of nanostructure-based photosensitizers for photodynamic cancer therapy. Small. 2014;10:4993–5013.Google Scholar
  134. Wang SZ, Gao RM, Zhou FM, Selke M. Nanomaterials and singlet oxygen photosensitizers: potential applications in photodynamic therapy. J Mater Chem. 2004;14:487–93.View ArticleGoogle Scholar
  135. Wang YH, Wang HG, Liu DP, Song SY, Wang X, Zhang HJ. Graphene oxide covalently grafted upconversion nanoparticles for combined NIR mediated imaging and photothermal/photodynamic cancer therapy. Biomaterials. 2013;34:7715–24.View ArticleGoogle Scholar
  136. Wang X, Yang CX, Chen JT, Yan XP. A dual-targeting upconversion nanoplatform for two-color fluorescence imaging-guided photodynamic therapy. Anal Chem. 2014;86:3263–7.View ArticleGoogle Scholar
  137. Wang GD, Nguyen HT, Chen H, Cox PB, Wang L, Nagata K, Hao Z, Wang A, Li Z, Xie J. X-ray induced photodynamic therapy: a combination of radiotherapy and photodynamic therapy. Theranostics. 2016;6:2295–305.View ArticleGoogle Scholar
  138. Weisman RB, Bachilo SM. Dependence of optical transition energies on structure for single-walled carbon nanotubes in aqueous suspension: an empirical Kataura plot. Nano Lett. 2003;3:1235–8.View ArticleGoogle Scholar
  139. Wojtoniszak M, Roginska D, Machalinski B, Drozdzik M, Mijowska E. Graphene oxide functionalized with methylene blue and its performance in singlet oxygen generation. Mater Res Bull. 2013;48:2636–9.View ArticleGoogle Scholar
  140. Wu W, Zhao J, Sun J, Guo S. Light-harvesting fullerene dyads as organic triplet photosensitizers for triplet–triplet annihilation upconversions. J Org Chem. 2012;77:5305–12.View ArticleGoogle Scholar
  141. Wu CH, He QM, Zhu AN, Li D, Xu M, Yang H, Liu YY. Synergistic anticancer activity of photo- and chemoresponsive nanoformulation based on polylysine-functionalized graphene. ACS Appl Mater Interfaces. 2014;6:21615–23.View ArticleGoogle Scholar
  142. Wu SY, An SSA, Hulme J. Current applications of graphene oxide in nanomedicine. Int J Nanomed. 2015;10:9–24.View ArticleGoogle Scholar
  143. Xia T, Zhao Y, Sager T, George S, Pokhrel S, Li N, Schoenfeld D, Meng H, Lin S, Wang X, Wang M, Ji Z, Zink JI, Madler L, Castranova V, Nel AE. Decreased dissolution of ZnO by iron doping yields nanoparticles with reduced toxicity in the rodent lung and zebrafish embryos. ACS Nano. 2011;5:1223–35.View ArticleGoogle Scholar
  144. Xiao HR, Zhu BS, Wang DL, Pang Y, He L, Ma XF, Wang RB, Jin CY, Chen Y, Zhu XY. Photodynamic effects of chlorin e6 attached to single wall carbon nanotubes through noncovalent interactions. Carbon. 2012;50:1681–9.View ArticleGoogle Scholar
  145. Xu W, Feng L, Wu YS, Wang TS, Wu JY, Xiang JF, Li B, Jiang L, Shu CY, Wang CR. Construction and photophysics study of supramolecular complexes composed of three-point binding fullerene-trispyridylporphyrin dyads and zinc porphyrin. PCCP. 2011;13:428–33.View ArticleGoogle Scholar
  146. Xu JS, Zeng F, Wu H, Yu CM, Wu SZ. Dual-targeting nanosystem for enhancing photodynamic therapy efficiency. ACS Appl Mater Interfaces. 2015;7:9287–96.View ArticleGoogle Scholar
  147. Yan L, Chang YN, Yin WY, Tian G, Zhou LJ, Liu XD, Xing GM, Zhao LN, Gu ZJ, Zhao YL. On-demand generation of singlet oxygen from a smart graphene complex for the photodynamic treatment of cancer cells. Biomater Sci. 2014;2:1412–8.View ArticleGoogle Scholar
  148. Yan X, Hu H, Lin J, Jin AJ, Niu G, Zhang S, Huang P, Shen B, Chen X. Optical and photoacoustic dual-modality imaging guided synergistic photodynamic/photothermal therapies. Nanoscale. 2015a;7:2520–6.View ArticleGoogle Scholar
  149. Yan XF, Niu G, Lin J, Jin AJ, Hu H, Tang YX, Zhang YJ, Wu AG, Lu J, Zhang SL, Huang P, Shen BZ, Chen XY. Enhanced fluorescence imaging guided photodynamic therapy of sinoporphyrin sodium loaded graphene oxide. Biomaterials. 2015b;42:94–102.View ArticleGoogle Scholar
  150. Yang X, Chen L, Qiao X, Fan C. Photo-induced damages of cytoplasmic and mitochondrial membranes by a [C-60] fullerene malonic acid derivative. Int J Toxicol. 2007;26:197–201.View ArticleGoogle Scholar
  151. Yang K, Zhang SA, Zhang GX, Sun XM, Lee ST, Liu ZA. Graphene in mice: ultrahigh in vivo tumor uptake and efficient photothermal therapy. Nano Lett. 2010;10:3318–23.View ArticleGoogle Scholar
  152. Yang Y, Zhang YM, Chen Y, Zhao D, Chen JT, Liu Y. Construction of a graphene oxide based noncovalent multiple nanosupramolecular assembly as a scaffold for drug delivery. Chem Eur J. 2012;18:4208–15.View ArticleGoogle Scholar
  153. Yano S, Hirohara S, Obata M, Hagiya Y, Ogura S-I, Ikeda A, Kataoka H, Tanaka M, Joh T. Current states and future views in photodynamic therapy. J Photochem Photobiol C. 2011;12:46–67.View ArticleGoogle Scholar
  154. Yao M, Ma L, Li L, Zhang J, Lim RX, Chen W, Zhang Y. A new modality for cancer treatment—nanoparticle mediated microwave induced photodynamic therapy. J Biomed Nanotechnol. 2016;12:1835–51.View ArticleGoogle Scholar
  155. Yu C, Avci P, Canteenwala T, Chiang LY, Chen BJ, Hamblin MR. Photodynamic therapy with hexa(sulfo-n-butyI)[60]fullerene against sarcoma in vitro and in vivo. J Nanosci Nanotechnol. 2016;16:171–81.View ArticleGoogle Scholar
  156. Zeng YP, Yang ZY, Luo SL, Li H, Liu C, Hao YH, Liu J, Wang WD, Li R. Fast and facile preparation of PEGylated graphene from graphene oxide by lysosome targeting delivery of photosensitizer to efficiently enhance photodynamic therapy. RSC Adv. 2015;5:57725–34.View ArticleGoogle Scholar
  157. Zhang Y, Chen W, Wang S, Liu Y, Pope C. Phototoxicity of zinc oxide nanoparticle conjugates in human ovarian cancer NIH: OVCAR-3 cells. J Biomed Nanotechnol. 2008;4:432–8.View ArticleGoogle Scholar
  158. Zhang W, Gong X, Liu C, Piao Y, Sun Y, Diao G. Water-soluble inclusion complex of fullerene with gamma-cyclodextrin polymer for photodynamic therapy. J Mater Chem B. 2014;2:5107–15.View ArticleGoogle Scholar
  159. Zhao CQ, Rehman FU, Yang YL, Li XQ, Zhang D, Jiang H, Selke M, Wang XM, Liu CY. Bio-imaging and photodynamic therapy with tetra sulphonatophenyl porphyrin (TSPP)-TiO2 nanowhiskers: new approaches in rheumatoid arthritis theranostics. Sci Rep. 2015;5:11518.View ArticleGoogle Scholar
  160. Zhao CQ, Rehman FU, Jiang H, Selke M, Wang XM, Liu CY. Titanium dioxide-tetra sulphonatophenyl porphyrin nanocomposites for target cellular bio-imaging and treatment of rheumatoid arthritis. Sci China Chem. 2016;59:637–42.View ArticleGoogle Scholar
  161. Zhou YH, Wang Y, Zhang XL, Peng JJ, Li HM, Li Z. Preparation and characterization of photosensitive and magnetic targeting graphene oxide nanocomposite. J Nanosci Nanotechnol. 2015;15:2009–14.View ArticleGoogle Scholar
  162. Zhu Z, Tang Z, Phillips JA, Yang R, Wang H, Tan W. Regulation of singlet oxygen generation using single-walled carbon nanotubes. J Am Chem Soc. 2008;130:10856–7.View ArticleGoogle Scholar

Copyright

© The Author(s) 2017